0001437749-23-009857 | 10-Q | XBRL Viewer

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 1. Basis of presentation and summary of significant accounting policies

The accompanying unaudited condensed interim consolidated financial statements (the “financial statements”) reflect the accounts of the Company for the quarterly period ended February 28, 2023. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the “Annual Financial Statements”) included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2022 (the “Annual Report”). These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

These condensed interim consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

All amounts in the unaudited condensed interim consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, unless otherwise indicated.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Annual Report.

On February 10, 2023, the Company divested its ownership interest in ASG Pharma Ltd., a wholly-owned subsidiary incorporated in Malta, and, therefore, it is no longer consolidated in the Company's results. The Company recognized a gain of $312 in other non-operating (losses) gains, net as a result of the disposal.

Marketable Securities

We classify term deposits and other investments that have maturities of greater than three months but less than one year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

Long-term investments

Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.

Convertible notes receivable

Convertible notes receivable include various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net income (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants and RSUs and the incremental shares issuable upon conversion of the convertible debentures payable and similar instruments.

In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three and nine months ended February 28, 2023, the dilutive potential common share equivalents outstanding consist of the following: 16,431,876 common shares from RSUs, 4,660,046 common shares from share options, 6,209,000 common shares from warrants and 36,388,651 common shares from convertible debentures payable.

Revenue

On July 12, 2022, the Company and HEXO entered into various commercial transaction agreements, as described in Note 23 (Segment reporting), which includes an advisory services arrangement. Revenue is recognized as the advisory services are provided to HEXO. Payments received for the services in advance of performance are recognized as a contract liability.

Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred/provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.

Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and other current liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.

In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.

In determining the transaction price for the sale of goods or service, the Company considers the effects of variable consideration and the existence of significant financing components, if any.

Some contracts for the sale of goods or services may provide customers with a right of return, volume discount, bonuses for volume/quality achievement, or sales allowance. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. These items give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method best predicts the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date.

New accounting pronouncements not yet adopted

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. ASU 2021-08 is effective for the Company beginning June 1, 2023. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

New accounting pronouncements recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. The Company adopted ASU 2020-06 beginning June 1, 2022 and the adoption did not have material retrospective impacts on our condensed interim consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. The Company adopted the ASU beginning June 1, 2022 and the adoption of ASU 2021-04 did not have an impact on our condensed interim consolidated financial statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance, which is intended to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The Company adopted the ASU beginning June 1, 2022 and the adoption of ASU 2021-04 did not have an impact on the disclosure in our condensed interim consolidated financial statements.

Note 2 - Inventory

9 Months Ended

Feb. 28, 2023

Inventory Disclosure [Text Block]

Note 2. Inventory

Inventory consisted of the following:

	*February 28,*		*May 31,*
	*2023*		*2022*
Plants	$	13,566	$	14,521
Dried cannabis		84,066		116,739
Cannabis trim		591		592
Cannabis derivatives		8,557		24,685
Cannabis vapes		2,631		542
Packaging and other inventory items		17,621		21,691
Wellness inventory		12,797		13,275
Beverage alcohol inventory		30,100		27,840
Distribution inventory		32,871		25,644
Total	$	202,800	$	245,529

During the three and nine months ended February 28, 2023, the Company recorded charges of $55,000 for an inventory valuation adjustment as a component of cannabis cost of good sold, compared to $nil and $12,000 for the three and nine months ended February 28, 2022. This charge was driven by the decision of management to repurpose a portion of our existing supply of dried cannabis inventory.

Note 3 - Capital Assets

9 Months Ended

Feb. 28, 2023

Property, Plant and Equipment Disclosure [Text Block]

Note 3. Capital assets

Capital assets consisted of the following:

	*February 28,*			*May 31,*
	*2023*			*2022*
Land	$	29,056		$	31,882
Production facility		353,630			453,412
Equipment		199,453			254,486
Leasehold improvement		7,764			7,455
Construction in progress		8,909			7,505
	$	598,812		$	754,740
Less: accumulated amortization		(173,549	)		(167,241	)
Total	$	425,263		$	587,499

The Company recorded non-cash impairments of $81,500 on its production facility in Canada and $22,500 on its equipment for the three and nine months ended February 28, 2023, which the Company has temporarily made idle in order to reduce cultivation costs and right-size the Company's production to align with current and projected demand. The impairment was calculated based on the excess of carrying value over fair value which was determined using a market approach. A reasonably possible change in any of the inputs within the determination of fair value would not result in a material change to the impairment recorded.

Note 4 - Intangible Assets

9 Months Ended

Feb. 28, 2023

Intangible Assets Disclosure [Text Block]

Note 4. Intangible Assets

Intangible assets consisted of the following items:

	*February 28,*			*May 31,*
	*2023*			*2022*
Customer relationships & distribution channel	$	613,461		$	617,437
Licenses, permits & applications		367,649			377,897
Non-compete agreements		13,644			12,512
Intellectual property, trademarks, knowhow & brands		585,777			634,997
		1,580,531		$	1,642,843
Less: accumulated amortization		(170,362	)	$	(154,124	)
Less: impairments		(415,844	)		(210,844	)
Total	$	994,325		$	1,277,875

The Company recorded non-cash impairments of $110,000 of its customer relationships & distribution channel, $55,000 of its licenses, permits & applications and $40,000 of its intellectual property, trademarks, knowhow & brands for the three and nine months ended February 28, 2023, as a result of the decline in market share in its Canadian cannabis with certain product lines and customers. As of February 28, 2023, included in licenses, permits & applications is $182,009 of indefinite-lived intangible assets. As of May 31, 2022, there was $248,411 of indefinite-lived intangible assets included in Licenses, permits & applications.

In calculating the impairment amount, using an income approach, the Company used a discount rate of 13.50%, increased from 11.21% used in the May 31, 2022 annual assessment, a terminal growth rate of 2%-5% consistent with the rate used in the May 31, 2022 annual assessment, and an average revenue growth rate of 0%-40% over 5 years to correlate with the cash flows anticipated with the individual intangible assets that were assessed, while these assets have not been assessed individually in the past the associated cash flows were included in the May 31, 2022 goodwill annual assessment which used an average growth rate of 46%. A reasonably possible change in any of the inputs within the determination of fair value would not result in a material change to the impairment recorded.

Expected future amortization expense for intangible assets as of February 28, 2023 are as follows:

	*Amortization*
2023 (remaining three months)	$	19,443
2024		75,720
2025		72,616
2026		72,616
2027		72,616
Thereafter		499,305
Total	$	812,316

Note 5 - Goodwill

9 Months Ended

Feb. 28, 2023

Goodwill Disclosure [Text Block]

Note 5. Goodwill

The following table shows the carrying amount of goodwill by reporting units:

	*February 28,*			*May 31,*
Reporting Unit	*2023*			*2022*
Cannabis	$	2,640,669		$	2,640,669
Distribution		4,458			4,458
Beverage alcohol		123,325			102,999
Wellness		77,470			77,470
Effect of foreign exchange		2,210			39,640
Impairments		(842,431	)		(223,931	)
Total	$	2,005,701		$	2,641,305

Based upon a combination of factors including a sustained decline in the Company’s market capitalization below the Company’s carrying value, coupled with challenging macro-economic conditions, most particularly the rising interest rate environment and slower than anticipated progress in global cannabis legalization, the Company concluded that it is more likely than not, that the fair value of our reporting units was less than their carrying amounts as at February 28, 2023. Accordingly, the Company valued the fair value of each reporting segment by using the income approach, which estimates the fair value of each reporting unit based on the future discounted cash flows. Upon updating the Company’s forecasted cash flows there were no impairments identified from changes in management’s forecasts, however, due to the increased borrowing rates and the decline of the company’s market capitalization, the Company was led to adjust the Company specific risk premium which resulted in the non-cash impairment charges of $603,500 of cannabis goodwill and $15,000 of wellness goodwill for the three and nine months ended February 28, 2023. The non-cash charge has no impact on the Company’s compliance with debt covenants, its cash flows or available liquidity.

In the Company's cannabis goodwill assessment the Company used a discount rate of 13.50%, increased from 11.21% used in the May 31, 2022 annual assessment, a terminal growth rate of 5% consistent with the rate used in the May 31, 2022 annual assessment, and an average revenue growth rate of 40% over 5 years as a result of anticipated federal legalization in various countries, decreased from 46% used in the May 31, 2022 annual assessment. A 1% increase in the discount rate would result in an additional $300,000 in impairment, a 1% decrease in the terminal growth rate would result in an additional $250,000 in impairment and a 5% decrease in the average growth rate would result in an additional $200,000 in impairment.

In the Company's wellness goodwill assessment the Company used a discount rate of 11.80%, increased from 10% used in the May 31, 2022 annual assessment, a terminal growth rate of 3% consistent with the rate used in the May 31, 2022 annual assessment, and an average revenue growth rate of 10% over 5 years, consistent with the rate used in the May 31, 2022 annual assessment. A 1% increase in the discount rate would result in an additional $14,000 in impairment, a 1% decrease in the terminal growth rate would result in an additional $10,000 in impairment and a 5% decrease in the average growth rate would result in an additional $5,000 in impairment.

Acquisition of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery)

On December 7, 2021, the Company through its wholly-owned subsidiary Four Twenty Corporation, acquired all the membership interests of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery), a Colorado limited liability company and a leading distilled spirits brand located in Breckenridge, Colorado (the “Breckenridge Acquisition”). In consideration for the Breckenridge Acquisition, the Company paid an aggregate amount equal to $114,068 through the issuance of 12,540,479 shares of Tilray’s Class 2 common shares.

The table below summarizes the fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

	*Amount*
Consideration
Shares	$	114,068
Net assets acquired
Current assets
Cash and cash equivalents		326
Accounts receivable		2,128
Prepaids and other current assets		367
Inventory		20,351
Long-term assets
Capital assets		11,179
Customer relationships (15 years)		9,800
Intellectual property, trademarks & brands (15 years)		69,950
Goodwill		2,797
Total Assets		116,898
Current liabilities
Accounts payable and accrued liabilities		2,228
Long-term liabilities
Deferred tax liability		602
Total liabilities		2,830
Total net assets acquired	$	114,068

The goodwill of $2,797 is primarily related to factors such as synergies and market opportunities and is reported under the Company’s Beverage alcohol segment. Revenue for the Company would have been higher by approximately $6,000 and $12,000 for the three and nine months ended February 28, 2022, if the acquisition had taken place on June 1, 2021. Net loss and comprehensive net loss would have increased by approximately $1,500 and $3,000 for the three and nine months ended February 28, 2022, if the acquisition had taken place on June 1, 2021, primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of Breckenridge.

Acquisition of Montauk Brewing Company, Inc.

On November 7, 2022, Tilray acquired Montauk Brewing Company, Inc. ("Montauk"), a leading craft brewer in Metro New York located in Montauk, New York (the “Montauk Acquisition”). In consideration for the Montauk Acquisition, the Company paid an initial purchase price of $35,110, which consisted of cash consideration of $28,688 and stock consideration of $6,422 through the issuance of 1,708,521 shares of Tilray's Class 2 common stock. In addition, the stockholders of Montauk shall be eligible to receive additional contingent cash consideration of up to $18,000 in the event that Montauk achieves certain volume and/or EBITDA targets on or before December 31, 2025. The Company determined that the closing date fair value of this contingent consideration was $10,245.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition date. During the three months ended February 28, 2023, the Company recorded measurement period adjustments to its initial allocation of purchase price as a result of ongoing valuation procedures on assets and liabilities assumed, included: (i) an increase in other liabilities of $3,750, related to identified unfavorable contracts with third party production companies; (ii) a decrease in deferred tax liability of $1,031; and (iii) an increase to goodwill of $2,719 due to the incremental period adjustments. The impact of measurement period adjustments to the results of operations was immaterial.

	*Amount*
Consideration
Cash	$	28,688
Shares		6,422
Contingent consideration		10,245
Net assets acquired
Current assets
Cash and cash equivalents		1,983
Accounts receivable		1,116
Prepaids and other current assets		467
Inventory		1,570
Long-term assets
Capital assets		420
Customer relationships (15 years)		16,570
Intellectual property, trademarks & brands (15 years)		12,430
Non-compete agreements (5 years)		1,240
Goodwill		20,326
Total Assets		56,122
Current liabilities
Accounts payable and accrued liabilities		1,580
Long-term liabilities
Deferred tax liability		5,437
Other liabilities		3,750
Total liabilities		10,767
Total net assets acquired	$	45,355

Revenue for the Company would have been higher by approximately $3,100 and $12,000 for the three and nine months ended February 28, 2023, if the acquisition had taken place on June 1, 2022. Net loss and comprehensive net loss would have increased by approximately $600 and $1,100 for the three and nine months ended February 28, 2023, if the acquisition had taken place on June 1, 2022, primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of Montauk.

Note 6 - Convertible Notes Receivable

9 Months Ended

Feb. 28, 2023

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

Note 6. Convertible notes receivable

Convertible notes receivable is comprised of the following:

	*February 28,*		*May 31,*
	*2023*		*2022*
HEXO Convertible Note	$	93,675	$	-
MedMen Convertible Note		74,681		111,200
Total convertible notes receivable		168,356		111,200
Deduct - current portion		-		-
Total convertible notes receivable, non current portion	$	168,356	$	111,200

HEXO Corp. ("HEXO")

On July 12, 2022, the Company closed a strategic alliance with HEXO, pursuant to which the Company acquired the HEXO Convertible Note from HT Investments MA LLC (“HTI”). At the time of closing, the HEXO Convertible Note had a principal balance of $173,700, which is to be repaid and or redeemed at 110% of the outstanding principal balance. The purchase price paid to HTI for the HEXO Convertible Note was $157,272. The purchase price paid to HTI was satisfied by Tilray's issuance of (i) a newly-issued $50,000 convertible promissory note ("HTI Convertible Note"), see Note 11 (Convertible debentures payable) and (ii) the remaining balance was paid through the issuance of 33,314,412 shares of Tilray's Class 2 common stock, par value $0.0001 (collectively, the “HTI Share Consideration”). The HEXO Convertible Note bears interest at a rate of 5.0% per annum, calculated daily, which is payable to Tilray on a semi-annual basis. Interest payments made under the HEXO Convertible Note will be paid in cash until July 12, 2023 and, thereafter, such interest shall accrue but be added to the principal amount. The HEXO Convertible Note has a maturity date of May 1, 2026. Subject to certain limitations and adjustments, the HEXO Convertible Note is convertible into HEXO Common Shares at Tilray's option at any time prior to the second scheduled trading day prior to the maturity date, at a conversion price of CAD$5.60 per HEXO Common share as determined the day before exercise, including all capitalized interest. HEXO has the ability to force the conversion if the daily VWAP per common share is equal to or exceeds $42.00 per share for twenty consecutive trading days. The conversion price was updated on December 19, 2022, from CAD$0.40 to CAD$5.60 to reflect HEXO's 14:1 reverse stock split. Under the HEXO Convertible Note, the Company holds a first-priority security interest on substantially all of HEXO’s assets. In the event of a default on the HEXO Convertible Note, the Company would be entitled to exercise its rights as a secured creditor, and the Note would become redeemable at 115% of the outstanding principal balance.

All third-party transaction costs associated with the acquisition of these notes were reimbursed by HEXO. During the three and nine months ended February 28, 2023, in connection with the HEXO Convertible Note, the Company recognized interest income of $2,171 and $5,549 respectively, and an other-than-temporary change in fair value which led to a non-cash impairment to the carrying value of the HEXO Convertible Note, which resulted in a loss of $63,597 for the three and nine months ended February 28, 2023. Due to changes in HEXO operations, which culminated in HEXO's assessment of a going concern issue regarding HEXO's ability to meet their minimum liquidity covenant, resulting in the Company increasing the forfeiture rate to 30% on the HEXO Convertible Note.

The HTI Share Consideration included a purchase price derivative, where the consideration paid is adjusted based on the sum of the VWAP of the Company's common stock for the 44 trading days after the issuance of the shares. The purchase price derivative is settled through the issuance of additional shares of the Company if the share price declined, or a cash payment back to the Company if the share price increased over the applicable period. On issuance this was valued at $nil. The subsequent change in fair value resulted in a gain of $18,256 due to the share price increasing, which was recorded in Transaction (income) costs, and was collected in cash by the Company during the period ended February 28, 2023.

The fair value of the HEXO Convertible Note was determined using the Black-Scholes model using the following assumptions: the risk-free rate of 3.50%; expected life of the convertible note; volatility of 90% based on comparable companies; forfeiture rate of 30%; dividend yield of nil and the exercise price of the respective conversion feature.

Concurrent with the aforementioned purchase of the HEXO Convertible Note, the Company and HEXO also entered into various commercial transaction agreements as described in Note 23 (Segment reporting).

MedMen Enterprises Inc. (“MedMen”)

On August 31, 2021, the Company issued 9,817,061 shares valued at $117,804 to acquire 68% interest in Superhero Acquisition L.P. (“SH Acquisition”), which purchased a senior secured convertible note (the "MedMen Convertible Note"), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured overnight financing rate ("SOFR") plus 6%, with a SOFR floor of 2.5% and, any accrued interest is added to the outstanding principal amount, and is to be paid at maturity of the MedMen Convertible Note. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity securities upon conversion of convertible securities that may be issued by MedMen. The Company’s ability to convert the MedMen Convertible Note and exercise the Warrants is dependent upon U.S. federal legalization of cannabis (a “Triggering Event”) or Tilray’s waiver of such requirement as well as any additional regulatory approvals. The MedMen Convertible Note has a maturity date of August 17, 2028.

During the three and nine months ended February 28, 2023, in connection with the Medmen Convertible Note, the Company recognized an other-than-temporary change in fair value, which resulted in a non-cash impairment expense of $117,778 which includes the reversal of the fair value adjustments which were previously recorded in accumulated other comprehensive loss. As a result, of the deterioration of capital market conditions from increased interest rates and recent delays in US Federal cannabis legalization, the Company increased the forfeiture rate to 30% on the Medmen Convertible Note and recorded the aforementioned loss on the Medmen Convertible Notes through impairments.

The Company recognized interest income, which is included as part of the convertible debentures in the amount of $3,474 and $10,480 for the three and nine months ended February 28, 2023. The Company also recognized unrealized gain (loss) on convertible notes receivable in other comprehensive income of $82,100 and $70,779 for the three and nine months ended February 28, 2023, $(39,296) and $(56,250) for the three months ended February 28, 2022.

The fair value of the MedMen Convertible Note was determined using the Black-Scholes model using the following assumptions: the risk-free rate of 3.50%; expected life of the convertible note; volatility of 70% based on comparable companies; forfeiture rate of nil; dividend yield of nil; probability of legalization between 0% and 60%; and, the exercise price of the respective conversion feature.

Note 7 - Long Term Investments

9 Months Ended

Feb. 28, 2023

Investment [Text Block]

Note 7. Long term investments

Long term investments consisted of the following:

	*February 28,*		*May 31,*
	*2023*		*2022*
Equity investments measured at fair value	$	1,972	$	4,347
Equity investments under measurement alternative		5,648		5,703
Total	$	7,620	$	10,050

Note 8 - Accounts Payable and Accrued Liabilities

9 Months Ended

Feb. 28, 2023

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 8. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities are comprised of:

	*February 28,*		*May 31,*
	*2023*		*2022*
Trade payables	$	67,065	$	68,604
Accrued liabilities		68,316		57,497
Accrued payroll and employment related taxes		14,736		17,736
Income taxes payable		9,371		6,150
Accrued interest		3,796		6,772
Other accruals		138		672
Total	$	163,422	$	157,431

Note 9 - Bank Indebtedness

9 Months Ended

Feb. 28, 2023

Short-Term Debt [Text Block]

Note 9. Bank indebtedness

Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000 which bears interest at the lender’s prime rate plus 75 basis points. As of February 28, 2023, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on that certain real property at 265 Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has three operating lines of credit for €8,000, €3,500, and €500 each, which bear interest at Euro Over Night Index Average plus 1.79% and Euro Interbank Offered Rate ("EURIBOR") plus 3.682% respectively. As of February 28, 2023, a total of €7,663 ($8,125) was drawn down from the available credit of €12,000. The operating lines of credit are secured by a security interest in the inventory of CC Pharma GmbH.

Four Twenty Corporation (“420”), a subsidiary of the Company, has a revolving credit facility of $30,000 which bears interest at EURIBOR plus an applicable margin. As of February 28, 2023, the Company has drawn $10,000 on the revolving line of credit. The revolving credit facility is secured by all of 420's assets and includes a corporate guarantee by a subsidiary of the Company.

Note 10 - Long-term Debt

9 Months Ended

Feb. 28, 2023

Long-Term Debt [Text Block]

Note 10. Long-term debt

The following table sets forth the net carrying amount of long-term debt instruments:

	*February 28,*			*May 31,*
	*2023*			*2022*
Credit facility - C$66,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2025	$	47,630		$	53,720
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$194 including interest, due in July 2033		11,322			12,750
Term loan - C$25,000 - Canadian prime plus 1.50%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly installments of C$190 including interest, due in April 2032		13,447			15,050
Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026		371			462
Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026		2,140			2,327
Term loan ‐ €5,000 ‐ EURIBOR plus 1.79%, 5‐year term, repayable in quarterly installments of €250 plus interest, due in December 2023		1,060			1,878
Term loan ‐ €1,500 ‐ EURIBOR plus 1.79%, 1‐year term, repayable in monthly installments of €100 plus interest, due in December 2023		1,064			—
Term loan ‐ €5,000 ‐ EURIBOR plus 2.68%, 5‐year term, repayable in quarterly installments of €250 plus interest, due in December 2023		1,060			1,878
Term loan ‐ €1,500 ‐ EURBIOR plus 2.00%, 5‐year term, repayable in quarterly installments of €98 including interest, due in April 2025		910			1,219
Term loan ‐ €1,500 ‐ EURIBOR plus 2.00%, 5‐year term, repayable in quarterly installments of €98 including interest, due in June 2025		994			1,307
Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, with a 10-year amortization, repayable in monthly installments of $57 plus interest, due in October 2030		21,041			21,561
Term loan - $100,000 - EURIBOR rate plus an applicable margin, 3-year term, repayable in quarterly installments of $2,500, due in December 2023		67,500			75,000
Carrying amount of long-term debt		168,539			187,152
Unamortized financing fees		(1,228	)		(1,450	)
Net carrying amount		167,311			185,702
Less principal portion included in current liabilities		(77,892	)		(67,823	)
Total noncurrent portion of long-term debt	$	89,419		$	117,879

On November 28, 2022, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) amending and restating the existing credit facility in the aggregate principal amount of C$66,000. The Amended and Restated Credit Agreement extended the term of the existing credit facility to November 28, 2025. The principal amount of loans outstanding at the time of the amendment was C$66,000.

As of February 28, 2023, the Company was in compliance with all of its covenants under its long-term debt agreements.

Note 11 - Convertible Debentures Payable

9 Months Ended

Feb. 28, 2023

Convertible Debentures [Text Block]

Note 11. Convertible debentures payable

The following table sets forth the net carrying amount of the convertible debentures payable:

	*February 28,*		*May 31,*
	*2023*		*2022*
HTI Convertible Note	$	45,762	$	—
5.25% Convertible Notes ("APHA 24")		223,087		216,753
5.00% Convertible Notes ("TLRY 23")		138,320		185,196
Total		407,169		401,949
Deduct - current portion		184,082		-
Total convertible debentures payable, non current portion	$	223,087	$	401,949

HTI Convertible Note

	*February 28,*			*May 31,*
	*2023*			*2022*
4.00% Contractual debenture	$	50,000		$	—
Unamortized discount		(4,238	)		—
Net carrying amount	$	45,762		$	—

On July 12, 2022, the Company issued a $50,000 convertible promissory note to HTI ("HTI Convertible Note"), bearing a 4% interest rate payable on a quarterly basis and having a maturity date of September 1, 2023. The fair value of the conversion feature was determined to be $9,055. Refer to Note 6 (Convertible notes receivable) for additional details on this transaction. HTI may convert the HTI Convertible Note, in whole or in part, at any time prior to the second trading day immediately preceding the maturity date, into shares of Common Stock at a conversion price equal to $4.03, which is calculated as 125% of the closing sale price as of the closing date ( July 12, 2022). In no event will HTI be allowed to effect a conversion of the HTI Convertible Note if such conversion, along with all other shares of Common Stock beneficially owned by HTI and its affiliates, would exceed 9.99% of the outstanding Common Stock (the "Beneficial Ownership Limitation"). If HTI does not elect or is unable to elect to convert under the Beneficial Ownership Limitation the Company will be responsible for repaying the HTI Convertible Note in cash.

APHA 24

	*February 28,*			*May 31,*
	*2023*			*2022*
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)
Fair value adjustment		(36,153	)		(42,487	)
Net carrying amount	$	223,087		$	216,753

Holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date of June 1, 2024. The initial conversion which the Company may settle in cash, or common shares of Tilray, or a combination thereof, at Tilray's election, is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events. In addition, holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time preceding December 1, 2023, if:

(a)

the last reported sales price of the common shares for at least 20 trading days during a period of 30 consecutive trading days immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

(b)

during the five-business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1 principal amount of the APHA 24 for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company’s common shares and the conversion rate on each such trading day;

(c)

the Company calls any or all of the APHA 24 for redemption or;

(d)

upon occurrence of a specified corporate event.

The Company may redeem for cash all or part of the Notes, at its option, if the last reported sale price of the Company’s common shares has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA 24 will be equal to 100% of the principal amount of $259,240 plus accrued and unpaid interest to, but excluding, the redemption date.

TLRY 23

	*February 28,*			*May 31,*
	*2023*			*2022*
5.00% Contractual debenture	$	277,856		$	277,856
Principal amount paid		(138,026	)		(88,026	)
Unamortized discount		(1,510	)		(4,634	)
Net carrying amount	$	138,320		$	185,196

During the nine months ended February 28, 2023, the Company repurchased outstanding TLRY 23 notes in the principal amount of $50,000, in exchange for a purchase price of $48,975. As a result of this transaction, the unamortized discount was reduced by $918 and a gain of $191 was recorded in non-operating income (expense), net.

The TLRY 23 bears interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. Additional interest may accrue on the TLRY 23 in specified circumstances. The TLRY 23 will mature on October 1, 2023, unless earlier repurchased, redeemed or converted. There are no principal payments required over the five-year term of the TLRY 23, except in the case of redemption or events of default.

The TLRY 23 is an unsecured obligation and ranks senior in right of payment to all of the Company's indebtedness that is expressly subordinated in right of payment to the TLRY 23; equal in right of payment with any of the Company's unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company's secured indebtedness to the extent the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of the Company's current or future subsidiaries.

Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election (the “cash conversion option”). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per one thousand dollar principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 835,275 shares of common stock, based on the $139,830 aggregate principal amount of convertible notes outstanding as of February 28, 2023. Throughout the term of the TLRY 23, the conversion rate may be adjusted upon the occurrence of certain events.

Prior to the close of business on the business day immediately preceding April 1, 2023, the TLRY 23 will be convertible only under the specified circumstances. On or after April 1, 2023 until the close of business on the business day immediately preceding the maturity date, September 30, 2023, holders may convert all or any portion of their TLRY 23, in multiples of $1 principal amount, at the option of the holder regardless of the aforementioned circumstances.

As of February 28, 2023, the Company was in compliance with all the covenants set forth under the TLRY 23. The effective interest rate on the debt is 6.9%, the Company recognized interest expense of $1,748 and $6,077 and amortized discount interest of $630 and $2,169 for the three and nine months ended February 28, 2023.

Note 12 - Warrant Liability

9 Months Ended

Feb. 28, 2023

Warrants [Text Block]

Note 12. Warrant liability

As of February 28, 2023 and May 31, 2022, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring March 17, 2025. Each warrant is exercisable for one common share of the Company.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the nine months ended February 28, 2023, the Company issued shares which triggered the anti-dilution price protection feature lowering the exercise price to $3.15. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

The Company estimated the fair value of the warrant liability at February 28, 2023 at $1.19 per warrant using the Black Scholes pricing model (Level 3) with the following assumptions: Risk-free interest rate of 3.94%, expected volatility of 70%, expected term of 2.55 years, strike price of $3.15 and fair value of common stock of $2.83.

Expected volatility is based on both historical and implied volatility of the Company’s common stock.

Note 13 - Stockholders' Equity

9 Months Ended

Feb. 28, 2023

Stockholders' Equity Note Disclosure [Text Block]

Note 13. Stockholders' equity

Series A Preferred Stock

On February 21, 2023, in connection with the issuance of the Consideration Shares, Tilray filed a certificate of designation (the "Certificate of Designation") with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of the Series A Preferred Stock.

General; No Transferability. Shares of Series A Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series A Preferred stock may be transferred by the holder thereof.

Voting Rights. The Certificate of Designation provides that each share of Preferred Stock will have 1,000 votes and will vote together with the outstanding shares of Class 2 common stock as a single class exclusively with respect to any proposal to adopt amendments to the Company’s amended and restated certificate of incorporation (as amended) (collectively, the “Charter Amendments”) by (a) eliminating provisions relating to the Company’s Class 1 common stock, par value $0.0001 per share (the “Class 1 Common Stock”), in connection with the previous automatic conversion of all issued and outstanding shares of Class 1 Common Stock into shares of Class 2 Common Stock, (b) reclassifying the authorized shares of Class 1 Common Stock as Class 2 Common Stock, and (c) adding a provision to automatically reclassify each issued and outstanding share of Class 2 Common Stock as one share of common stock, par value $0.0001, of the Company (“Common Stock”), the cumulative result being the Company having only two classes of stock authorized for issuance — common stock and preferred stock.

The Series A Preferred Stock will be voted, without action by the holder, on any such proposal in the same proportion as shares of Class 2 Common Stock are voted. The Series A Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware.

Dividends. Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Class-2-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares of the Class 2 Common Stock when, as and if such dividends are paid on shares of the Class 2 Common Stock. No other dividends shall be paid on shares of Series A Preferred Stock.

Rank Liquidation. The Series A Preferred Stock ranks pari passu with the Class 2 Common Stock as to any distribution of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.

Automatic Conversion. Upon the closing of the polls at any meeting of the Company’s stockholders held for the purpose of voting on the Charter Amendments (taking into account any adjournment or postponement thereof), each issued and outstanding share of Series A Preferred Stock will, without any further action on the part of the holder thereof or the Company, automatically be converted (the “Automatic Conversion”) into a number of fully paid and nonassessable shares of Common Stock as determined by dividing the Stated Value (as defined by the Certificate of Designation) by the Conversion Price then in effect. The conversion price per share upon an Automatic Conversion for the Series A Preferred Stock shall be the Stated Value of such share, subject to adjustment in the event that the Conversion Price then in effect is equal to or less than the Minimum Price, as defined in Nasdaq Listing Rule 5635(d)(1)(A) (the “Conversion Price”) see Note 24 (Subsequent events).

Issued and outstanding

As of February 28, 2023, the Company had 990,000,000 shares authorized to be issued, of which 243,333,333 are Class 1 shares, with nil shares issued and outstanding, 736,666,667 are Class 2 shares, with 613,181,559 shares issued and outstanding and 10,000,000 are Series A Preferred Stock with 120,000 shares issued and outstanding.

During the nine months ended February 28, 2023, the Company issued the following Class 2 shares:

32,481,149 shares under its At-the-Market (“ATM”) program for gross proceeds of $132,238. The Company paid $2,645 in commissions and other fees associated with these issuances for net proceeds of $129,593.

	b)	33,314,412 shares to purchase the HEXO convertible notes receivable.
	c)	15,994,406 shares to settle amounts owed to the non-controlling shareholders of Aphria Diamond in the amount of $59,731.

1,683,656 shares for the exercise of various stock-based compensation awards.

1,708,521 shares issued to acquire Montauk Brewing Company Inc.

During the nine months ended February 28, 2023, the Company issued the following Series A preferred stock shares:

120,000 shares to settle amounts owed to the non-controlling shareholders of Aphria Diamond in the amount of $334

The Company maintains stock-based compensation plans as disclosed in our Annual Financial Statements. For the three and nine months ended February 28, 2023, the total stock-based compensation was $ 9,630 and $ 29,766, whereas for the three and nine months ended February 28, 2022, total stock based compensation was $9,355 and $27,025 respectively.

During the three and nine months ended February 28, 2023, the Company granted nil and 6,004,995 time-based RSUs and nil and 2,634,744 performance based RSUs ( February 28, 2022 - nil and 69,508 time-based RSUs and nil and 1,414,666 performance based RSUs). The Company's total stock-based compensation expense recognized is as follows:

	*For the three months*				*For the nine months*
	*ended February 28,*				*ended February 28,*
	*2023*		*2022*		*2023*		*2022*
Stock options	$	20	$	273	$	644	$	4,968
RSUs		9,610		9,082		29,122		22,057
Total	$	9,630	$	9,355	$	29,766	$	27,025

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

Note 14 - Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Feb. 28, 2023

Comprehensive Income (Loss) Note [Text Block]

Note 14. Accumulated other comprehensive income (loss)

Accumulated other comprehensive loss includes the following components:

				*Unrealized*
	*Foreign*			*loss on*
	*currency*			*convertible*
	*translation*			*notes*
	*gain (loss)*			*receivables*			*Total*
Balance May 31, 2022	$	54,413		$	(75,177	)	$	(20,764	)
Other comprehensive loss		(56,443	)		(2,525	)		(58,968	)
Balance August 31, 2022	$	(2,030	)	$	(77,702	)	$	(79,732	)
Other comprehensive loss		(24,080	)		(17,643	)		(41,723	)
Balance November 30, 2022	$	(26,110	)	$	(95,345	)	$	(121,455	)
Other comprehensive (loss) reversal		(16,838	)		95,345			78,507
Balance February 28, 2023	$	(42,948	)	$	—		$	(42,948	)

Note 15 - Non-controlling Interests

9 Months Ended

Feb. 28, 2023

Noncontrolling Interest Disclosure [Text Block]

Note 15. Non-controlling interests

The following tables summarize the information relating to the Company’s subsidiaries, SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations.

Summary of balance sheet information of the entities in which there is a non-controlling interest as of February 28, 2023:

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Current assets	$	—	$	163		$	94,103		$	157		$	94,423
Non-current assets		74,681		—			139,749			3,025			217,455
Current liabilities		—		(713	)		(13,468	)		(39	)		(14,220	)
Non-current liabilities		—		(405	)		(176,071	)		(6,455	)		(182,931	)
Net assets	$	74,681	$	(955	)	$	44,313		$	(3,312	)	$	114,727

Summary of balance sheet information of the entities there is a non-controlling interest as of May 31, 2022:

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*May 31,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*
Current assets	$	—	$	485		$	20,546		$	193		$	21,224
Non-current assets		111,200		158			152,786			93,738			357,882
Current liabilities		—		(642	)		(63,196	)		(53	)		(63,891	)
Non-current liabilities		—		(410	)		(29,653	)		(6,537	)		(36,600	)
Net assets	$	111,200	$	(409	)	$	80,483		$	87,341		$	278,615

Summary of income statement information of the entities in which there is a non-controlling interest for the nine months ended February 28, 2023:

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Revenue	$	—		$	126		$	98,960		$	—		$	99,086
Total expenses		107,297			659			54,285			91,026			253,267
Net (loss) income		(107,297	)		(533	)		44,675			(91,026	)		(154,181	)
Other comprehensive (loss) income		70,778			(13	)		(707	)		373			70,431
Net comprehensive (loss) income	$	(36,519	)	$	(546	)	$	43,968		$	(90,653	)	$	(83,750	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(11,686	)		(137	)		21,544			(9,065	)		656
Additional income attributable to NCI		—			—			8,968			—			8,968
Net comprehensive (loss) income attributable to NCI	$	(11,686	)	$	(137	)	$	30,512		$	(9,065	)	$	9,624

Summary of income statement information of the entities in which there is a non-controlling interest for the nine months ended February 28, 2022:

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*
Revenue	$	—		$	354		$	88,470		$	—		$	88,824
Total expenses		(7,568	)		431			47,841			(192	)		40,512
Net (loss) income		7,568			(77	)		40,629			192			48,312
Other comprehensive (loss) income		(55,601	)		30			(2,509	)		(2,203	)		(60,283	)
Net comprehensive (loss) income	$	(48,033	)	$	(47	)	$	38,120		$	(2,011	)	$	(11,971	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(15,371	)	$	(12	)	$	18,679		$	(201	)	$	3,095

Note 16 - Income Taxes

9 Months Ended

Feb. 28, 2023

Income Tax Disclosure [Text Block]

Note 16. Income taxes

The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock-based compensation, amortization of intangibles, and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax recovery of $(10,811) and $(15,313) for the three and nine months ended February 28, 2023, and income tax recovery of $(1,830) and $(2,739) for the three and nine months ended February 28, 2022. The income tax expense in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Note 17 - Commitments and Contingencies

9 Months Ended

Feb. 28, 2023

Commitments and Contingencies Disclosure [Text Block]

Note 17. Commitments and contingencies

Purchase and other commitments

The Company has payments on long-term debt, refer to Note 10 (Long-term debt), convertible notes, refer to Note 11 (Convertible debentures payable), material purchase commitments and construction commitments as follows:

	*Total*		*2024*		*2025*		*2026*		*2027*		*Thereafter*
Long-term debt repayment	$	168,539	$	77,892	$	11,157	$	40,435	$	4,743	$	34,312
Convertible notes		449,070		189,830		259,240		—		—		—
Material purchase obligations		26,878		19,946		5,515		840		239		338
Construction commitments		5,433		5,433		—		—		—		—
Total	$	649,920	$	293,101	$	275,912	$	41,275	$	4,982	$	34,650

The following table presents the future undiscounted payment associated with lease liabilities as of February 28, 2023:

	*Operating*
	*leases*
2023	$	3,979
2024		3,337
2025		3,521
2026		3,417
Thereafter		4,928
Total minimum lease payments	$	19,182
Imputed interest		(8,056	)
Obligations recognized	$	11,126

Legal proceedings

There have been no material changes from the legal proceedings since our fiscal quarter ended November 30, 2022, except with respect to certain aspects of the legal proceedings disclosed below:

Class Action Suits and Stockholder Derivative Suits

Approved Settlement of Tilray Brands, Inc. Reorganization Litigation (Delaware, New York) – Special Litigation Committee

On February 27, 2020, Tilray stockholders Deborah Braun and Nader Noorian filed a class action and derivative complaint in the Delaware Court of Chancery styled Braun v. Kennedy, C.A. No. 2020-0137-KSJM. On March 2, 2020, Tilray stockholders Catherine Bouvier, James Hawkins, and Stephanie Hawkins filed a class action and derivative complaint in the Delaware Court of Chancery styled Bouvier v. Kennedy, C.A. No. 2020-0154-KSJM.

On March 4, 2020, the Delaware Court of Chancery entered an order consolidating the two cases and designating the complaint in the Braun/Noorian action as the operative complaint. The operative complaint asserts claims for breach of fiduciary duty against Brendan Kennedy, Christian Groh, Michael Blue, and Privateer Evolution, LLC (the “Privateer Defendants”) for alleged breaches of fiduciary duty in their alleged capacities as Tilray’s controlling stockholders and against Kennedy, Maryscott Greenwood, and Michael Auerbach for alleged breaches of fiduciary duties in their capacities as directors and/or officers of Tilray in connection with the prior merger of Privateer Holdings, Inc. with and into a wholly owned subsidiary (the “Downstream Merger”). The complaint alleges that the Privateer Defendants breached their fiduciary duties by causing Tilray to enter into the Downstream Merger and Tilray’s Board to approve that Downstream Merger, and that Defendants Kennedy, Greenwood, and Auerbach breached their fiduciary duties as directors by approving the Downstream Merger. Plaintiffs allege that the Downstream Merger gave the Privateer Defendants hundreds of millions of dollars of tax savings without providing a corresponding benefit to Tilray and its minority stockholders and that the Downstream Merger unfairly transferred and extended Kennedy, Blue, and Groh’s control over Tilray.

In August 2021, the Company’s Board of Directors established a Special Litigation Committee (the “SLC”) of independent directors to re-assert director control and investigate the derivative claims in this litigation matter. The SLC has appointed the law firm Wilson Sonsini to assist the SLC with an ongoing investigation of the underlying claim and determine whether continued prosecution of such claims was in the best interests of the Company.

On May 27, 2022, the SLC informed the Court that it had completed its investigation; determined not to seek dismissal of the Action; and confirmed its determination that the Company had suffered significant damages and that the SLC would pursue claims to recover appropriate amounts for the Company's benefit. Thereafter, the SLC, all of the Defendants, and certain non-parties participated in two mediation sessions before former Chancellor of the Delaware Court of Chancery Andre G. Bouchard.

On July 15, 2022, the SLC reached an agreement in principle with the Defendants and certain of the non-parties, and their respective insurers, to resolve the claims asserted in the Action in exchange for an aggregate amount of $26,900 to be paid to Tilray plus mutual releases. The SLC subsequently reached a further agreement with an additional non-party and plaintiffs to settle the entire Action. On December 20, 2022, the parties submitted to the Delaware Court of Chancery a Stipulation and Agreement of Compromise, Settlement, and Release ("SLC Settlement") which provided for, among other things, an aggregate cash amount of $39,900 to be paid to Tilray in exchange for mutual releases. Tilray stockholders will not receive any direct payment from the SLC Settlement. The SLC Settlement was formally approved by the Delaware Court following a hearing on February 27, 2023, and Tilray received the settlement proceeds following such approval.

Authentic Brands Group Related Class Action (New York, United States)

On May 4, 2020, Ganesh Kasilingam filed a lawsuit in the United States District Court for the Southern District of New York (“SDNY”), against Tilray Brands, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Kasilingam litigation”). The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company’s revenue sharing agreement with Authentic Brands Group (“ABG”), announced on January 15, 2019, and that the plaintiff suffered losses when Tilray’s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on March 2, 2020. On August 6, 2020, SDNY entered an order appointing Saul Kassin as Lead Plaintiff and The Rosen Law Firm, P.A. as Lead Counsel. Lead Plaintiff filed an amended complaint on October 5, 2020, which asserts the same Sections 10(b) and 20(a) claims against the same defendants on largely the same theory, and includes new allegations that Tilray’s reported inventory, cost of sales, and gross margins in its financial reports during the class period were false and misleading because Tilray improperly recorded unsellable “trim” as inventory and understated the cost of sales for its products.

On September 27, 2021, the U.S. District Court entered an Opinion & Order granting the Defendants’ motion to dismiss the complaint in the Kasilingam litigation. On December 3, 2021, the lead plaintiff filed a second amended complaint alleging similar claims against Tilray and Brendan Kennedy. The defendants moved to dismiss the amended complaint on February 2, 2022. On September 28, 2022, the Court granted in part and denied in part the defendants’ motion to dismiss the second amended complaint. On October 12, 2022, the Company filed a motion for reconsideration and/or interlocutory appeal of this Court decision. The Company still believes the claims are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome.

Aphria Inc. Securities Litigation (New York, United States)

On December 5, 2018, a putative securities class action was commenced in SDNY against a number of defendants including Aphria and certain current and former officers and directors. The action claims that the defendants misrepresented the value of three cannabis-producing properties Aphria acquired in Jamaica, Colombia, and Argentina (the “LATAM Assets”). On December 3, 2018, two notorious short-sellers issued a report about the acquisitions, claiming the LATAM Assets were non-functional or non-existent, which allegedly caused Aphria’s stock price to fall. On April 15, 2019, Aphria took impairment charges on the LATAM Assets, which also allegedly caused Aphria’s stock price to decline. The putative class action claims that Aphria artificially inflated the price of its publicly-traded stock by making false statements about the LATAM Assets, and when the purported truth was revealed by a short-seller report and write-down, the stock price declined, harming investors.

On September 30, 2020, the Court denied the motion to dismiss the complaint as to Aphria, Vic Neufeld, and Carl Merton, and granted the motion as to Cole Cacciavillani, John Cervini, Andrew DeFrancesco, and SOL Global Investments. On October 1, 2020, Plaintiffs moved for reconsideration of the order dismissing DeFrancesco and SOL or, in the alternative, to amend their complaint. On October 14, 2020, Aphria, Neufeld, and Merton moved for reconsideration of the order denying their motion to dismiss.

On September 29, 2021, the U.S. District Court issued an Order that (i) permitted the plaintiffs to amend their lawsuit to revive the claims against Andy DeFrancecso; and (ii) declined to revisit his decision that claims could proceed against Aphria/Tilray, Vic Neufeld, and Carl Merton. Plaintiffs declined to amend their complaint, however, and so the action is proceeding solely against Aphria/Tilray, Neufeld, and Merton. On December 5, 2022, the parties engaged in a mediation session with an independent mediator. However, no settlement agreement was reached.

It is too early to determine any potential damages from this proceeding. The Company and the individual defendants believe the claims are without merit, and intend to vigorously defend against the claims, but there can be no assurances as to the outcome.

LATAM and Nuuvera Class Actions and Individual Actions (Canada)

On January 29, 2018, Aphria announced the acquisition of Nuuvera Inc. On July 17, 2018, Aphria announced a planned expansion into Latin America and the Caribbean with the acquisition of LATAM Holdings Inc. The following class actions and four individual proceedings have been commenced in Canada against Aphria and several current or former officers relating to the Nuuvera and LATAM transactions:

(i) a proposed class action (the "Vecchio Action") commenced in the Ontario Superior Court in February 2019, and amended thereafter, alleging statutory and common law misrepresentations and oppression relating to the Nuuvera and LATAM transactions. The Vecchio Action names Aphria, Merton, Neufeld, Cacciavillani and 5 underwriters as defendants;

(ii) four individual actions (the "Individual Actions") commenced by Wan, Bergerson, Landry, and Profinsys in the Ontario Superior Court alleging statutory and common law misrepresentations relating to the LATAM and Nuuvera transactions. The Individual Actions name Aphria, Merton, Neufeld, and Cacciavillani as defendants.

In the Vecchio Action a motion for certification and leave was heard. For Reasons for Decision released August 6, 2021, and with the consent of Aphria and the individually named Defendants, the Court granted leave to proceed with the secondary market statutory cause of action, and certified the Action on behalf of a defined class of purchasers. Also, on consent, the Court dismissed the claims of oppression and common law misrepresentation against Aphria and the individual defendants, as well as all claims against Carl Merton. The Court granted certification of the primary market statutory cause of action against all remaining Defendants but made it conditional on a successful motion by the Plaintiff to have the Court appoint a second Plaintiff for that aspect of the Claim. The defendant underwriters are appealing one term of that final aspect of the Court's decision. We continue to believe that these claims are without merit and plan to vigorously defend against this action.

Docklight Litigation

On November 5, 2021 Docklight Brands, Inc. (“Docklight”) filed a complaint against the Company and its wholly-owned subsidiary, High Park Holdings, Ltd. (“High Park”) in Superior Court of the State of Washington, King County. Docklight claimed breach of contract against High Park arising from a 2018 license agreement pursuant to which Docklight licensed certain Bob Marley-related brands to High Park (as amended in 2020 and 2021, the “High Park License”). In addition, Docklight brought a negligent misrepresentation claim against Tilray, alleging that certain individuals at Tilray or Aphria had made false statements to Docklight in order to induce Docklight to waive Docklight’s alleged right to terminate the High Park License for change-of-control on the basis of the 2021 Tilray-Aphria Arrangement Agreement. Docklight seeks injunctive relief as well as unspecified damages. On December 17, 2021, Defendants removed the case to the United States District Court, Federal District of Washington. Defendants’ answer to the complaint was timely filed by January 21, 2022, and discovery in this litigation matter is ongoing. Tilray and High Park continue to believe that the claims are without merit and we intend to continue to vigorously defend the Docklight suit.

Included in Litigation (recovery) costs is $33,000 relating to the SLC Settlement (net of costs) and expense accruals equaling $25,000 to cover various ongoing litigation matters that are probable and estimable, for the three and nine months ended February 28, 2023.

Note 18 - Net Revenue

9 Months Ended

Feb. 28, 2023

Revenue from Contract with Customer [Text Block]

Note 18. Net revenue

The Company reports its net revenue in four reporting segments: cannabis, distribution, beverage alcohol and wellness.

Net revenue is comprised of:

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Cannabis revenue	$	61,118		$	69,178		$	203,503		$	232,540
Cannabis excise taxes		(13,569	)		(14,133	)		(47,486	)		(48,271	)
Net cannabis revenue		47,549			55,045			156,017			184,269
Beverage alcohol revenue		21,941			20,473			67,209			51,500
Beverage alcohol excise taxes		(1,301	)		(876	)		(4,520	)		(2,735	)
Net beverage alcohol revenue		20,640			19,597			62,689			48,765
Distribution revenue		65,385			62,532			186,158			198,587
Wellness revenue		12,015			14,697			38,072			43,426
Total	$	145,589		$	151,871		$	442,936		$	475,047

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Note 19 - Cost of Goods Sold

9 Months Ended

Feb. 28, 2023

Cost of Goods Sold [Text Block]

Note 19. Cost of goods sold

Cost of goods sold is comprised of:

	*For the three months*				*For the nine months*
	*ended February 28,*				*ended February 28,*
	*2023*		*2022*		*2023*		*2022*
Cannabis costs	$	80,362	$	37,042	$	137,800	$	122,492
Beverage alcohol costs		10,663		8,091		32,932		20,674
Distribution costs		57,964		57,566		165,443		178,093
Wellness costs		8,299		9,343		26,964		30,238
Total	$	157,288	$	112,042	$	363,139	$	351,497

Note 20 - General and Administrative Expenses

9 Months Ended

Feb. 28, 2023

General and Administrative Expenses [Text Block]

Note 20. General and administrative expenses

General and administrative expenses are comprised of:

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Executive compensation	$	2,754		$	4,238		$	9,359		$	9,565
Office and general		6,799			4,012			20,011			21,755
Salaries and wages		13,621			14,076			38,407			37,536
Stock-based compensation		9,630			9,355			29,766			27,025
Insurance		3,159			4,835			8,588			14,461
Professional fees		1,165			3,601			5,385			9,669
Gain on sale of capital assets		(15	)		(861	)		(2	)		(631	)
Insurance proceeds		-			(4,032	)		-			(4,032	)
Travel and accommodation		1,104			1,102			3,484			2,876
Rent		782			2,119			2,387			3,177
Total	$	38,999		$	38,445		$	117,385		$	121,401

Note 21 - Non-operating Income (Expense)

9 Months Ended

Feb. 28, 2023

Other Nonoperating Income and Expense [Text Block]

Note 21. Non-operating income (expense)

Non-operating income (expense) is comprised of:

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Change in fair value of convertible debenture payable	$	207		$	56,128		$	(20,375	)	$	151,851
Change in fair value of warrant liability		5,256			21,089			6,841			58,802
Foreign exchange loss		(1,955	)		(2,548	)		(26,621	)		(18,452	)
Loss on long-term investments		(925	)		(3,326	)		(2,529	)		(6,834	)
Other non-operating (losses) gains, net		(1,370	)		(306	)		(7,545	)		962
Total	$	1,213		$	71,037		$	(50,229	)	$	186,329

Other non-operating (losses) gains, net for the three and nine months ended February 28, 2023, includes amounts to settle outstanding notes with non-controlling interest shareholders.

Note 22 - Fair Value Measurements

9 Months Ended

Feb. 28, 2023

Fair Value Disclosures [Text Block]

Note 22. Fair value measurements

Financial instruments

The Company has classified its financial instruments as described in Note 3 Significant accounting policies in our Annual Financial Statements.

The carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

At February 28, 2023 the Company had long-term debt of $nil ( May 31, 2022 - $20,358) subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2023 and May 31, 2022 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

								*February 28,*
	*Level 1*		*Level 2*		*Level 3*			*2023*
Financial assets
Cash and cash equivalents	$	164,997	$	—	$	—		$	164,997
Marketable Securities		243,286		—		—			243,286
Convertible notes receivable		—		—		168,356			168,356
Equity investments measured at fair value		376		1,596		5,648			7,620
Financial liabilities
Warrant liability		—		—		(7,414	)		(7,414	)
Contingent consideration		—		—		(26,815	)		(26,815	)
APHA 24 Convertible debenture		—		—		(223,087	)		(223,087	)
Total recurring fair value measurements	$	408,659	$	1,596	$	(83,312	)	$	326,943

								*May 31,*
	*Level 1*		*Level 2*		*Level 3*			*2022*
Financial assets
Cash and cash equivalents	$	415,909	$	—	$	—		$	415,909
Convertible notes receivable		—		—		111,200			111,200
Equity investments measured at fair value		1,878		2,469		5,703			10,050
Financial liabilities
Warrant liability		—		—		(14,255	)		(14,255	)
Contingent consideration		—		—		(16,007	)		(16,007	)
APHA 24 Convertible debenture		—		—		(216,753	)		(216,753	)
Total recurring fair value measurements	$	417,787	$	2,469	$	(130,112	)	$	290,144

The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable, and equity investments are recorded at fair value. The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows and is classified as Level 3.

Debt securities classified as available-for sale are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 2. Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level 1.The Company classified securities without a quoted market price as Level 3.

The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

The contingent consideration from the acquisitions of SweetWater and Montauk, due in December 2023 and December 2025, respectively and payable in cash, is determined by discounting future expected cash outflows at a discount rate of 5%, and 11.4%, respectively and probability of achievement of 25% and 80%. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level 3.

The APHA 24 Convertible debentures payable are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3.

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

										*APHA 24*
	*Convertible*			*Warrant*			*Contingent*			*Convertible*
	*notes receivable*			*Liability*			*Consideration*			*Debt*			*Total*
Balance, May 31, 2022	$	111,200		$	(14,255	)	$	(16,007	)	$	(216,753	)	$	(135,815	)
Additions		167,752			—			(10,245	)		—			157,507
Unrealized gain (loss) on fair value		70,779			6,841			(563	)		(6,334	)		70,723
Impairments		(181,375	)		—			—			—			(181,375	)
Balance, February 28, 2023	$	168,356		$	(7,414	)	$	(26,815	)	$	(223,087	)	$	(88,960	)

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:

		*Significant*
	*Valuation*	*unobservable*
Financial asset / financial liability	*technique*	*input*	*Inputs*
		Volatility,	70%
APHA Convertible debentures	Black-Scholes	forfeiture rate,	30%
		expected life (in years)	1.3
Warrant liability	Black-Scholes	Volatility,	70%
		expected life (in years)	2.0
Contingent consideration	Discounted cash flows	Discount rate,	5% - 11%
		achievement	25% - 80%
Convertible notes receivable	Black-Scholes	Effective interest rate,	17% - 22%
		conversion	0% - 60%

Items measured at fair value on a non-recurring basis

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Note 23 - Segment Reporting

9 Months Ended

Feb. 28, 2023

Segment Reporting Disclosure [Text Block]

Note 23. Segment reporting

Information reported to the Chief Operating Decision Maker (“CODM”) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in four reportable segments: (1) cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (2) beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products, (3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and (4) wellness products, which encompasses hemp foods and cannabidiol (“CBD”) products. This structure is in line with how our Chief Operating Decision Maker (“CODM”) assesses our performance and allocates resources.

Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis.

Segment gross profit from external customers:

	*For the three months*					*For the nine months*
	*ended February 28,*					*ended February 28,*
	*2023*			*2022*		*2023*		*2022*
Cannabis
Net cannabis revenue	$	47,549		$	55,045	$	156,017	$	184,269
Cannabis costs		80,362			37,042		137,800		122,492
Gross profit (loss)		(32,813	)		18,003		18,217		61,777
Distribution
Distribution revenue		65,385			62,532		186,158		198,587
Distribution costs		57,964			57,566		165,443		178,093
Gross profit		7,421			4,966		20,715		20,494
Beverage alcohol
Net beverage alcohol revenue		20,640			19,597		62,689		48,765
Beverage alcohol costs		10,663			8,091		32,932		20,674
Gross profit		9,977			11,506		29,757		28,091
Wellness
Wellness revenue		12,015			14,697		38,072		43,426
Wellness costs		8,299			9,343		26,964		30,238
Gross profit	$	3,716		$	5,354	$	11,108	$	13,188

Channels of Cannabis revenue were as follows:

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Revenue from Canadian medical cannabis products	$	6,035		$	7,050		$	18,920		$	23,353
Revenue from Canadian adult-use cannabis products		45,318			43,504		$	156,063			162,632
Revenue from wholesale cannabis products		58			2,804		$	686			6,763
Revenue from international cannabis products		9,707			15,820		$	27,834			39,792
Less excise taxes		(13,569	)		(14,133	)	$	(47,486	)		(48,271	)
Total	$	47,549		$	55,045		$	156,017		$	184,269

On July 12, 2022, Tilray acquired the HEXO Convertible Note from HTI and also entered into a strategic alliance with HEXO Corp. (“HEXO”) as discussed in Note 6 (Convertible notes receivable) and Note 11 (Convertible debentures payable). In addition, the Company and HEXO entered into various commercial transaction agreements, including (i) an advisory services agreement regarding Tilray’s provision of advisory services to HEXO in exchange for an $18 million annual advisory fee payable to Tilray; (ii) a co-manufacturing agreement providing for third-party manufacturing services between the parties and setting forth the terms of Tilray’s international bulk supply to HEXO; and (iii) a procurement and cost savings agreement for shared savings related to specified optimization activities, procurement, and other similar cost savings realized by the parties as a result of the foregoing commercial arrangements.

Included in revenue from Canadian adult-use cannabis is $8,667 and $24,302 of advisory services revenue for the three and nine months ended February 28, 2023 from the aforementioned HEXO commercial transaction agreements.

Geographic net revenue:

	*For the three months*				*For the nine months*
	*ended February 28,*				*ended February 28,*
	*2023*		*2022*		*2023*		*2022*
North America	$	70,463	$	73,234	$	228,866	$	236,220
EMEA		71,111		74,671		199,867		225,596
Rest of World		4,015		3,966		14,203		13,231
Total	$	145,589	$	151,871	$	442,936	$	475,047

Geographic capital assets:

	*February 28,*		*May 31,*
	*2023*		*2022*
North America	$	313,233	$	464,370
EMEA		108,944		119,409
Rest of World		3,086		3,720
Total	$	425,263	$	587,499

Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the three and nine months ended February 28, 2023 and 2022, there were no major customers representing greater than 10% of our quarterly revenues.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

Note 24 - Subsequent Events

9 Months Ended

Feb. 28, 2023

Subsequent Events [Text Block]

Note 24. Subsequent Events

Charter Amendments

On March 16, 2023, the Company's stockholders formally approved the Company's proposal to amend its certificate of incorporation (the "Charter Amendments"). The Charter Amendments modified the Company's existing certificate of incorporation by canceling the Class 1 Common Stock and re-allocating such authorized shares to Class 2 Common Stock. In addition, the Charter Amendments reclassified each issued and outstanding share of Class 2 Common Stock as one share of Common Stock, par value $0.0001, of the Company (“Common Stock”). The cumulative effect of the Charter Amendments is that the Company currently has two classes of authorized stock — Common Stock and preferred stock. All of the issued and outstanding Series A Preferred Stock automatically converted into the Company’s common stock following the approval of the Charter Amendments by the vote of the Company’s stockholders. There are no outstanding Series A Preferred Stock following such automatic conversion.

Arrangement Agreement with HEXO Corp.

On April 10, 2023, we entered into an Arrangement Agreement (the “Arrangement Agreement”) with HEXO Corp. (“HEXO”), pursuant to which Tilray agreed to acquire all of the issued and outstanding common shares of HEXO pursuant to a plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Under the terms of the Arrangement Agreement, each outstanding common share of HEXO outstanding immediately prior to the effective time of the Arrangement is expected to be transferred to Tilray in exchange for 0.4352 of a share of Tilray Common Stock.

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Feb. 28, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Annual Report. On February 10, 2023, the Company divested its ownership interest in ASG Pharma Ltd., a wholly-owned subsidiary incorporated in Malta, and, therefore, it is no longer consolidated in the Company's results. The Company recognized a gain of $312 in other non-operating (losses) gains, net as a result of the disposal.
Marketable Securities, Policy [Policy Text Block]	Marketable Securities We classify term deposits and other investments that have maturities of greater than three months but less than one year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.
Investment, Policy [Policy Text Block]	Long-term investments Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”. Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.
Financing Receivable [Policy Text Block]	Convertible notes receivable Convertible notes receivable include various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).
Earnings Per Share, Policy [Policy Text Block]	Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net income (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants and RSUs and the incremental shares issuable upon conversion of the convertible debentures payable and similar instruments. In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three and nine months ended February 28, 2023, the dilutive potential common share equivalents outstanding consist of the following: 16,431,876 common shares from RSUs, 4,660,046 common shares from share options, 6,209,000 common shares from warrants and 36,388,651 common shares from convertible debentures payable.
Revenue [Policy Text Block]	Revenue On July 12, 2022, the Company and HEXO entered into various commercial transaction agreements, as described in Note 23 (Segment reporting), which includes an advisory services arrangement. Revenue is recognized as the advisory services are provided to HEXO. Payments received for the services in advance of performance are recognized as a contract liability. Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred/provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations. Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and other current liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority. In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates. In determining the transaction price for the sale of goods or service, the Company considers the effects of variable consideration and the existence of significant financing components, if any. Some contracts for the sale of goods or services may provide customers with a right of return, volume discount, bonuses for volume/quality achievement, or sales allowance. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. These items give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method best predicts the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date.
New Accounting Pronouncements, Policy [Policy Text Block]	New accounting pronouncements not* yet adopted* In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. ASU 2021-08 is effective for the Company beginning June 1, 2023. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU. New accounting pronouncements recently adopted In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. The Company adopted ASU 2020-06 beginning June 1, 2022 and the adoption did not have material retrospective impacts on our condensed interim consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. The Company adopted the ASU beginning June 1, 2022 and the adoption of ASU 2021-04 did not have an impact on our condensed interim consolidated financial statements. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance, which is intended to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The Company adopted the ASU beginning June 1, 2022 and the adoption of ASU 2021-04 did not have an impact on the disclosure in our condensed interim consolidated financial statements.

Disclosure of accounting policy for financing receivable.

Note 2 - Inventory (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Inventory, Current [Table Text Block]

	*February 28,*		*May 31,*
	*2023*		*2022*
Plants	$	13,566	$	14,521
Dried cannabis		84,066		116,739
Cannabis trim		591		592
Cannabis derivatives		8,557		24,685
Cannabis vapes		2,631		542
Packaging and other inventory items		17,621		21,691
Wellness inventory		12,797		13,275
Beverage alcohol inventory		30,100		27,840
Distribution inventory		32,871		25,644
Total	$	202,800	$	245,529

Note 3 - Capital Assets (Tables)

9 Months Ended

Feb. 28, 2023

Property, Plant and Equipment [Table Text Block]

	*February 28,*			*May 31,*
	*2023*			*2022*
Land	$	29,056		$	31,882
Production facility		353,630			453,412
Equipment		199,453			254,486
Leasehold improvement		7,764			7,455
Construction in progress		8,909			7,505
	$	598,812		$	754,740
Less: accumulated amortization		(173,549	)		(167,241	)
Total	$	425,263		$	587,499

Note 4 - Intangible Assets (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	*February 28,*			*May 31,*
	*2023*			*2022*
Customer relationships & distribution channel	$	613,461		$	617,437
Licenses, permits & applications		367,649			377,897
Non-compete agreements		13,644			12,512
Intellectual property, trademarks, knowhow & brands		585,777			634,997
		1,580,531		$	1,642,843
Less: accumulated amortization		(170,362	)	$	(154,124	)
Less: impairments		(415,844	)		(210,844	)
Total	$	994,325		$	1,277,875

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	*Amortization*
2023 (remaining three months)	$	19,443
2024		75,720
2025		72,616
2026		72,616
2027		72,616
Thereafter		499,305
Total	$	812,316

Note 5 - Goodwill (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Goodwill [Table Text Block]

	*February 28,*			*May 31,*
Reporting Unit	*2023*			*2022*
Cannabis	$	2,640,669		$	2,640,669
Distribution		4,458			4,458
Beverage alcohol		123,325			102,999
Wellness		77,470			77,470
Effect of foreign exchange		2,210			39,640
Impairments		(842,431	)		(223,931	)
Total	$	2,005,701		$	2,641,305

Acquisition of Montauk Brewing Company, Inc. [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	*Amount*
Consideration
Cash	$	28,688
Shares		6,422
Contingent consideration		10,245
Net assets acquired
Current assets
Cash and cash equivalents		1,983
Accounts receivable		1,116
Prepaids and other current assets		467
Inventory		1,570
Long-term assets
Capital assets		420
Customer relationships (15 years)		16,570
Intellectual property, trademarks & brands (15 years)		12,430
Non-compete agreements (5 years)		1,240
Goodwill		20,326
Total Assets		56,122
Current liabilities
Accounts payable and accrued liabilities		1,580
Long-term liabilities
Deferred tax liability		5,437
Other liabilities		3,750
Total liabilities		10,767
Total net assets acquired	$	45,355

Breckenridge [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	*Amount*
Consideration
Shares	$	114,068
Net assets acquired
Current assets
Cash and cash equivalents		326
Accounts receivable		2,128
Prepaids and other current assets		367
Inventory		20,351
Long-term assets
Capital assets		11,179
Customer relationships (15 years)		9,800
Intellectual property, trademarks & brands (15 years)		69,950
Goodwill		2,797
Total Assets		116,898
Current liabilities
Accounts payable and accrued liabilities		2,228
Long-term liabilities
Deferred tax liability		602
Total liabilities		2,830
Total net assets acquired	$	114,068

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Note 6 - Convertible Notes Receivable (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	*February 28,*		*May 31,*
	*2023*		*2022*
HEXO Convertible Note	$	93,675	$	-
MedMen Convertible Note		74,681		111,200
Total convertible notes receivable		168,356		111,200
Deduct - current portion		-		-
Total convertible notes receivable, non current portion	$	168,356	$	111,200

Note 7 - Long Term Investments (Tables)

9 Months Ended

Feb. 28, 2023

Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]

	*February 28,*		*May 31,*
	*2023*		*2022*
Equity investments measured at fair value	$	1,972	$	4,347
Equity investments under measurement alternative		5,648		5,703
Total	$	7,620	$	10,050

Note 8 - Accounts Payable and Accrued Liabilities (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	*February 28,*		*May 31,*
	*2023*		*2022*
Trade payables	$	67,065	$	68,604
Accrued liabilities		68,316		57,497
Accrued payroll and employment related taxes		14,736		17,736
Income taxes payable		9,371		6,150
Accrued interest		3,796		6,772
Other accruals		138		672
Total	$	163,422	$	157,431

Note 10 - Long-term Debt (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Long-Term Debt Instruments [Table Text Block]

	*February 28,*			*May 31,*
	*2023*			*2022*
Credit facility - C$66,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2025	$	47,630		$	53,720
Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$194 including interest, due in July 2033		11,322			12,750
Term loan - C$25,000 - Canadian prime plus 1.50%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly installments of C$190 including interest, due in April 2032		13,447			15,050
Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026		371			462
Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026		2,140			2,327
Term loan ‐ €5,000 ‐ EURIBOR plus 1.79%, 5‐year term, repayable in quarterly installments of €250 plus interest, due in December 2023		1,060			1,878
Term loan ‐ €1,500 ‐ EURIBOR plus 1.79%, 1‐year term, repayable in monthly installments of €100 plus interest, due in December 2023		1,064			—
Term loan ‐ €5,000 ‐ EURIBOR plus 2.68%, 5‐year term, repayable in quarterly installments of €250 plus interest, due in December 2023		1,060			1,878
Term loan ‐ €1,500 ‐ EURBIOR plus 2.00%, 5‐year term, repayable in quarterly installments of €98 including interest, due in April 2025		910			1,219
Term loan ‐ €1,500 ‐ EURIBOR plus 2.00%, 5‐year term, repayable in quarterly installments of €98 including interest, due in June 2025		994			1,307
Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, with a 10-year amortization, repayable in monthly installments of $57 plus interest, due in October 2030		21,041			21,561
Term loan - $100,000 - EURIBOR rate plus an applicable margin, 3-year term, repayable in quarterly installments of $2,500, due in December 2023		67,500			75,000
Carrying amount of long-term debt		168,539			187,152
Unamortized financing fees		(1,228	)		(1,450	)
Net carrying amount		167,311			185,702
Less principal portion included in current liabilities		(77,892	)		(67,823	)
Total noncurrent portion of long-term debt	$	89,419		$	117,879

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

Note 11 - Convertible Debentures Payable (Tables)

9 Months Ended

Feb. 28, 2023

Convertible Debt [Table Text Block]

	*February 28,*		*May 31,*
	*2023*		*2022*
HTI Convertible Note	$	45,762	$	—
5.25% Convertible Notes ("APHA 24")		223,087		216,753
5.00% Convertible Notes ("TLRY 23")		138,320		185,196
Total		407,169		401,949
Deduct - current portion		184,082		-
Total convertible debentures payable, non current portion	$	223,087	$	401,949

	*February 28,*			*May 31,*
	*2023*			*2022*
4.00% Contractual debenture	$	50,000		$	—
Unamortized discount		(4,238	)		—
Net carrying amount	$	45,762		$	—

	*February 28,*			*May 31,*
	*2023*			*2022*
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)
Fair value adjustment		(36,153	)		(42,487	)
Net carrying amount	$	223,087		$	216,753

	*February 28,*			*May 31,*
	*2023*			*2022*
5.00% Contractual debenture	$	277,856		$	277,856
Principal amount paid		(138,026	)		(88,026	)
Unamortized discount		(1,510	)		(4,634	)
Net carrying amount	$	138,320		$	185,196

Note 13 - Stockholders' Equity (Tables)

9 Months Ended

Feb. 28, 2023

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	*For the three months*				*For the nine months*
	*ended February 28,*				*ended February 28,*
	*2023*		*2022*		*2023*		*2022*
Stock options	$	20	$	273	$	644	$	4,968
RSUs		9,610		9,082		29,122		22,057
Total	$	9,630	$	9,355	$	29,766	$	27,025

Note 14 - Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

				*Unrealized*
	*Foreign*			*loss on*
	*currency*			*convertible*
	*translation*			*notes*
	*gain (loss)*			*receivables*			*Total*
Balance May 31, 2022	$	54,413		$	(75,177	)	$	(20,764	)
Other comprehensive loss		(56,443	)		(2,525	)		(58,968	)
Balance August 31, 2022	$	(2,030	)	$	(77,702	)	$	(79,732	)
Other comprehensive loss		(24,080	)		(17,643	)		(41,723	)
Balance November 30, 2022	$	(26,110	)	$	(95,345	)	$	(121,455	)
Other comprehensive (loss) reversal		(16,838	)		95,345			78,507
Balance February 28, 2023	$	(42,948	)	$	—		$	(42,948	)

Note 15 - Non-controlling Interests (Tables)

9 Months Ended

Feb. 28, 2023

Condensed Balance Sheet [Table Text Block]

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Current assets	$	—	$	163		$	94,103		$	157		$	94,423
Non-current assets		74,681		—			139,749			3,025			217,455
Current liabilities		—		(713	)		(13,468	)		(39	)		(14,220	)
Non-current liabilities		—		(405	)		(176,071	)		(6,455	)		(182,931	)
Net assets	$	74,681	$	(955	)	$	44,313		$	(3,312	)	$	114,727

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*May 31,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*
Current assets	$	—	$	485		$	20,546		$	193		$	21,224
Non-current assets		111,200		158			152,786			93,738			357,882
Current liabilities		—		(642	)		(63,196	)		(53	)		(63,891	)
Non-current liabilities		—		(410	)		(29,653	)		(6,537	)		(36,600	)
Net assets	$	111,200	$	(409	)	$	80,483		$	87,341		$	278,615

Condensed Income Statement [Table Text Block]

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Revenue	$	—		$	126		$	98,960		$	—		$	99,086
Total expenses		107,297			659			54,285			91,026			253,267
Net (loss) income		(107,297	)		(533	)		44,675			(91,026	)		(154,181	)
Other comprehensive (loss) income		70,778			(13	)		(707	)		373			70,431
Net comprehensive (loss) income	$	(36,519	)	$	(546	)	$	43,968		$	(90,653	)	$	(83,750	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(11,686	)		(137	)		21,544			(9,065	)		656
Additional income attributable to NCI		—			—			8,968			—			8,968
Net comprehensive (loss) income attributable to NCI	$	(11,686	)	$	(137	)	$	30,512		$	(9,065	)	$	9,624

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*
Revenue	$	—		$	354		$	88,470		$	—		$	88,824
Total expenses		(7,568	)		431			47,841			(192	)		40,512
Net (loss) income		7,568			(77	)		40,629			192			48,312
Other comprehensive (loss) income		(55,601	)		30			(2,509	)		(2,203	)		(60,283	)
Net comprehensive (loss) income	$	(48,033	)	$	(47	)	$	38,120		$	(2,011	)	$	(11,971	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(15,371	)	$	(12	)	$	18,679		$	(201	)	$	3,095

Note 17 - Commitments and Contingencies (Tables)

9 Months Ended

Feb. 28, 2023

Contractual Obligation, Fiscal Year Maturity [Table Text Block]

	*Total*		*2024*		*2025*		*2026*		*2027*		*Thereafter*
Long-term debt repayment	$	168,539	$	77,892	$	11,157	$	40,435	$	4,743	$	34,312
Convertible notes		449,070		189,830		259,240		—		—		—
Material purchase obligations		26,878		19,946		5,515		840		239		338
Construction commitments		5,433		5,433		—		—		—		—
Total	$	649,920	$	293,101	$	275,912	$	41,275	$	4,982	$	34,650

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

	*Operating*
	*leases*
2023	$	3,979
2024		3,337
2025		3,521
2026		3,417
Thereafter		4,928
Total minimum lease payments	$	19,182
Imputed interest		(8,056	)
Obligations recognized	$	11,126

Note 18 - Net Revenue (Tables)

9 Months Ended

Feb. 28, 2023

Disaggregation of Revenue [Table Text Block]

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Cannabis revenue	$	61,118		$	69,178		$	203,503		$	232,540
Cannabis excise taxes		(13,569	)		(14,133	)		(47,486	)		(48,271	)
Net cannabis revenue		47,549			55,045			156,017			184,269
Beverage alcohol revenue		21,941			20,473			67,209			51,500
Beverage alcohol excise taxes		(1,301	)		(876	)		(4,520	)		(2,735	)
Net beverage alcohol revenue		20,640			19,597			62,689			48,765
Distribution revenue		65,385			62,532			186,158			198,587
Wellness revenue		12,015			14,697			38,072			43,426
Total	$	145,589		$	151,871		$	442,936		$	475,047

Note 19 - Cost of Goods Sold (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Cost of Goods Sold [Table Text Block]

	*For the three months*				*For the nine months*
	*ended February 28,*				*ended February 28,*
	*2023*		*2022*		*2023*		*2022*
Cannabis costs	$	80,362	$	37,042	$	137,800	$	122,492
Beverage alcohol costs		10,663		8,091		32,932		20,674
Distribution costs		57,964		57,566		165,443		178,093
Wellness costs		8,299		9,343		26,964		30,238
Total	$	157,288	$	112,042	$	363,139	$	351,497

Note 20 - General and Administrative Expenses (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of General and Administrative Expenses [Table Text Block]

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Executive compensation	$	2,754		$	4,238		$	9,359		$	9,565
Office and general		6,799			4,012			20,011			21,755
Salaries and wages		13,621			14,076			38,407			37,536
Stock-based compensation		9,630			9,355			29,766			27,025
Insurance		3,159			4,835			8,588			14,461
Professional fees		1,165			3,601			5,385			9,669
Gain on sale of capital assets		(15	)		(861	)		(2	)		(631	)
Insurance proceeds		-			(4,032	)		-			(4,032	)
Travel and accommodation		1,104			1,102			3,484			2,876
Rent		782			2,119			2,387			3,177
Total	$	38,999		$	38,445		$	117,385		$	121,401

Note 21 - Non-operating Income (Expense) (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Change in fair value of convertible debenture payable	$	207		$	56,128		$	(20,375	)	$	151,851
Change in fair value of warrant liability		5,256			21,089			6,841			58,802
Foreign exchange loss		(1,955	)		(2,548	)		(26,621	)		(18,452	)
Loss on long-term investments		(925	)		(3,326	)		(2,529	)		(6,834	)
Other non-operating (losses) gains, net		(1,370	)		(306	)		(7,545	)		962
Total	$	1,213		$	71,037		$	(50,229	)	$	186,329

Note 22 - Fair Value Measurements (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

								*February 28,*
	*Level 1*		*Level 2*		*Level 3*			*2023*
Financial assets
Cash and cash equivalents	$	164,997	$	—	$	—		$	164,997
Marketable Securities		243,286		—		—			243,286
Convertible notes receivable		—		—		168,356			168,356
Equity investments measured at fair value		376		1,596		5,648			7,620
Financial liabilities
Warrant liability		—		—		(7,414	)		(7,414	)
Contingent consideration		—		—		(26,815	)		(26,815	)
APHA 24 Convertible debenture		—		—		(223,087	)		(223,087	)
Total recurring fair value measurements	$	408,659	$	1,596	$	(83,312	)	$	326,943

								*May 31,*
	*Level 1*		*Level 2*		*Level 3*			*2022*
Financial assets
Cash and cash equivalents	$	415,909	$	—	$	—		$	415,909
Convertible notes receivable		—		—		111,200			111,200
Equity investments measured at fair value		1,878		2,469		5,703			10,050
Financial liabilities
Warrant liability		—		—		(14,255	)		(14,255	)
Contingent consideration		—		—		(16,007	)		(16,007	)
APHA 24 Convertible debenture		—		—		(216,753	)		(216,753	)
Total recurring fair value measurements	$	417,787	$	2,469	$	(130,112	)	$	290,144

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

										*APHA 24*
	*Convertible*			*Warrant*			*Contingent*			*Convertible*
	*notes receivable*			*Liability*			*Consideration*			*Debt*			*Total*
Balance, May 31, 2022	$	111,200		$	(14,255	)	$	(16,007	)	$	(216,753	)	$	(135,815	)
Additions		167,752			—			(10,245	)		—			157,507
Unrealized gain (loss) on fair value		70,779			6,841			(563	)		(6,334	)		70,723
Impairments		(181,375	)		—			—			—			(181,375	)
Balance, February 28, 2023	$	168,356		$	(7,414	)	$	(26,815	)	$	(223,087	)	$	(88,960	)

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

		*Significant*
	*Valuation*	*unobservable*
Financial asset / financial liability	*technique*	*input*	*Inputs*
		Volatility,	70%
APHA Convertible debentures	Black-Scholes	forfeiture rate,	30%
		expected life (in years)	1.3
Warrant liability	Black-Scholes	Volatility,	70%
		expected life (in years)	2.0
Contingent consideration	Discounted cash flows	Discount rate,	5% - 11%
		achievement	25% - 80%
Convertible notes receivable	Black-Scholes	Effective interest rate,	17% - 22%
		conversion	0% - 60%

Note 23 - Segment Reporting (Tables)

9 Months Ended

Feb. 28, 2023

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	*For the three months*					*For the nine months*
	*ended February 28,*					*ended February 28,*
	*2023*			*2022*		*2023*		*2022*
Cannabis
Net cannabis revenue	$	47,549		$	55,045	$	156,017	$	184,269
Cannabis costs		80,362			37,042		137,800		122,492
Gross profit (loss)		(32,813	)		18,003		18,217		61,777
Distribution
Distribution revenue		65,385			62,532		186,158		198,587
Distribution costs		57,964			57,566		165,443		178,093
Gross profit		7,421			4,966		20,715		20,494
Beverage alcohol
Net beverage alcohol revenue		20,640			19,597		62,689		48,765
Beverage alcohol costs		10,663			8,091		32,932		20,674
Gross profit		9,977			11,506		29,757		28,091
Wellness
Wellness revenue		12,015			14,697		38,072		43,426
Wellness costs		8,299			9,343		26,964		30,238
Gross profit	$	3,716		$	5,354	$	11,108	$	13,188

	*For the three months*						*For the nine months*
	*ended February 28,*						*ended February 28,*
	*2023*			*2022*			*2023*			*2022*
Revenue from Canadian medical cannabis products	$	6,035		$	7,050		$	18,920		$	23,353
Revenue from Canadian adult-use cannabis products		45,318			43,504		$	156,063			162,632
Revenue from wholesale cannabis products		58			2,804		$	686			6,763
Revenue from international cannabis products		9,707			15,820		$	27,834			39,792
Less excise taxes		(13,569	)		(14,133	)	$	(47,486	)		(48,271	)
Total	$	47,549		$	55,045		$	156,017		$	184,269

Revenue from External Customers by Geographic Areas [Table Text Block]

	*For the three months*				*For the nine months*
	*ended February 28,*				*ended February 28,*
	*2023*		*2022*		*2023*		*2022*
North America	$	70,463	$	73,234	$	228,866	$	236,220
EMEA		71,111		74,671		199,867		225,596
Rest of World		4,015		3,966		14,203		13,231
Total	$	145,589	$	151,871	$	442,936	$	475,047

Long-Lived Assets by Geographic Areas [Table Text Block]

	*February 28,*		*May 31,*
	*2023*		*2022*
North America	$	313,233	$	464,370
EMEA		108,944		119,409
Rest of World		3,086		3,720
Total	$	425,263	$	587,499

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 10, 2023	Feb. 28, 2023	Feb. 28, 2023
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants (in shares)		6,209,000	6,209,000
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities (in shares)		36,388,651	36,388,651
Restricted Stock Units (RSUs) [Member]
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (in shares)		16,431,876	16,431,876
Share-Based Payment Arrangement, Option [Member]
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements (in shares)		4,660,046	4,660,046
ASG Pharma Ltd. [Member]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ 312

Note 2 - Inventory (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Inventory Write-down			$ 55,000	$ 12,000
Cannabis [Member]
Inventory Write-down	$ 55,000	$ 0	$ 55,000	$ 12,000

Note 2 - Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Inventory	$ 202,800	$ 245,529
Plants [Member]
Inventory	13,566	14,521
Dried Cannabis [Member]
Inventory	84,066	116,739
Cannabis Trim [Member]
Inventory	591	592
Cannabis Derivatives [Member]
Inventory	8,557	24,685
Cannabis Vapes [Member]
Inventory	2,631	542
Packaging and Other Inventory Items [Member]
Inventory	17,621	21,691
Wellness Inventory [Member]
Inventory	12,797	13,275
Beverage Alcohol Inventory [Member]
Inventory	30,100	27,840
Distribution Inventory [Member]
Inventory	$ 32,871	$ 25,644

Note 3 - Capital Assets (Details Textual) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Feb. 28, 2023	Feb. 28, 2023
Manufacturing Facility [Member] \| CANADA
Impairment, Long-Lived Asset, Held-for-Use, Total	$ 81.5	$ 81.5
Equipment [Member]
Impairment, Long-Lived Asset, Held-for-Use, Total	$ 22.5	$ 22.5

Note 3 - Capital Assets - Schedule of Capital Assets (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Property, plant and equipment, gross	$ 598,812	$ 754,740
Less: accumulated amortization	(173,549)	(167,241)
Total	425,263	587,499
Land [Member]
Property, plant and equipment, gross	29,056	31,882
Manufacturing Facility [Member]
Property, plant and equipment, gross	353,630	453,412
Equipment [Member]
Property, plant and equipment, gross	199,453	254,486
Leasehold Improvements [Member]
Property, plant and equipment, gross	7,764	7,455
Construction in Progress [Member]
Property, plant and equipment, gross	$ 8,909	$ 7,505

Note 4 - Intangible Assets (Details Textual) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
Note 4 - Intangible Assets (Details Textual) $ in Thousands	Feb. 28, 2023 USD ($)	Feb. 28, 2023 USD ($)	May 31, 2022 USD ($)
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 415,844	$ 210,844
Measurement Input, Discount Rate [Member]
Impairment of Intangible Assets, Measurement Input	0.1350	0.1350	0.1121
Measurement Input, Terminal Growth Rate [Member] \| Minimum [Member]
Impairment of Intangible Assets, Measurement Input			0.02
Measurement Input, Terminal Growth Rate [Member] \| Maximum [Member]
Impairment of Intangible Assets, Measurement Input			0.05
Measurement Input, Average Revenue Growth Rate [Member] \| Minimum [Member]
Impairment of Intangible Assets, Measurement Input			0
Measurement Input, Average Revenue Growth Rate [Member] \| Maximum [Member]
Impairment of Intangible Assets, Measurement Input			0.40
Measurement Input, Expected Term [Member]
Impairment of Intangible Assets, Measurement Input			5
Cash Flows Anticipated With Individual Intangible Assets [Member]
Impairment of Intangible Assets, Measurement Input			0.46
Licenses, Permits and Applications [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance	$ 182,009	$ 182,009	$ 248,411
Customer Relationships and Distribution Channel [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	110,000
Licenses, Permits and Applications [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	55,000	55,000
Intellectual Property, Trademarks, Know How and Brands [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 40,000	$ 40,000

Note 4 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2023	Feb. 28, 2023	May 31, 2022
Cost	$ 1,580,531	$ 1,580,531	$ 1,642,843
Less: accumulated amortization	(170,362)	(170,362)	(154,124)
Less: impairments		(415,844)	(210,844)
Total	994,325	994,325	1,277,875
Customer Relationships and Distribution Channel [Member]
Cost	613,461	613,461	617,437
Less: impairments	(110,000)
Licenses, Permits and Applications [Member]
Cost	367,649	367,649	377,897
Less: impairments	(55,000)	(55,000)
Noncompete Agreements [Member]
Cost	13,644	13,644	12,512
Intellectual Property, Trademarks, Know How and Brands [Member]
Cost	585,777	585,777	$ 634,997
Less: impairments	$ (40,000)	$ (40,000)

Note 4 - Intangible Assets-Schedule of Estimated Amortization Expense (Details) $ in Thousands	Feb. 28, 2023 USD ($)
2023 (remaining three months)	$ 19,443
2024	75,720
2025	72,616
2026	72,616
2027	72,616
Thereafter	499,305
Total	$ 812,316

Note 5 - Goodwill (Details Textual) $ in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
Note 5 - Goodwill (Details Textual) $ in Thousands	Nov. 07, 2022 USD ($) shares	Dec. 07, 2021 USD ($) shares	Feb. 28, 2023 USD ($)	Feb. 28, 2022 USD ($)	Feb. 28, 2023 USD ($)	Feb. 28, 2022 USD ($)	May 31, 2022 USD ($)
Goodwill, Impairment Loss					$ 842,431		$ 223,931
Goodwill, Ending Balance			$ 2,005,701		2,005,701		2,641,305
Breckenridge [Member]
Business Combination, Consideration Transferred, Total		$ 114,068
Goodwill, Ending Balance		2,797
Business Acquisition, Pro Forma Revenue			6,000		12,000
Business Acquisition, Pro Forma Net Income (Loss)				$ (1,500)		$ (3,000)
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 114,068
Breckenridge [Member] \| Common Class Two [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) \| shares		12,540,479
Acquisition of Montauk Brewing Company, Inc. [Member]
Business Combination, Consideration Transferred, Total	$ 35,110
Goodwill, Ending Balance	20,326
Business Acquisition, Pro Forma Revenue			3,100		12,000
Business Acquisition, Pro Forma Net Income (Loss)			(600)		(1,100)
Payments to Acquire Businesses, Gross	28,688
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	6,422
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	18,000
Business Combination, Contingent Consideration, Liability, Total	10,245
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Liabilities	3,750
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities	(1,031)
Goodwill, Purchase Accounting Adjustments	$ 2,719
Acquisition of Montauk Brewing Company, Inc. [Member] \| Common Class 2 [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) \| shares	1,708,521
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 6,422
Cannabis Segment [Member]
Goodwill, Impairment Loss					603,500
Goodwill, Impairment Loss, Increase From 1% of Increase in Discount Rate					300,000
Goodwill, Impairment Loss, Increase From 1% of Decrease in Terminal Growth Rate					250,000
Goodwill, Impairment Loss, Increase From 5% of Decrease in Average Growth Rate					200,000
Goodwill, Ending Balance			$ 2,640,669		$ 2,640,669		$ 2,640,669
Cannabis Segment [Member] \| Measurement Input, Discount Rate [Member]
Goodwill, Measurement Input			0.1350		0.1350		0.1121
Cannabis Segment [Member] \| Measurement Input, Terminal Growth Rate [Member]
Goodwill, Measurement Input			0.05		0.05		0.05
Cannabis Segment [Member] \| Measurement Input, Average Revenue Growth Rate [Member]
Goodwill, Measurement Input			0.40		0.40		0.46
Wellness Business [Member]
Goodwill, Impairment Loss			$ 15,000
Goodwill, Impairment Loss, Increase From 1% of Increase in Discount Rate					$ 14,000
Goodwill, Impairment Loss, Increase From 1% of Decrease in Terminal Growth Rate					10,000
Goodwill, Impairment Loss, Increase From 5% of Decrease in Average Growth Rate					5,000
Goodwill, Ending Balance			$ 77,470		$ 77,470		$ 77,470
Wellness Business [Member] \| Measurement Input, Discount Rate [Member]
Goodwill, Measurement Input			0.1180		0.1180		0.10
Wellness Business [Member] \| Measurement Input, Terminal Growth Rate [Member]
Goodwill, Measurement Input			0.03		0.03		0.03
Wellness Business [Member] \| Measurement Input, Average Revenue Growth Rate [Member]
Goodwill, Measurement Input			0.10		0.10		0.10

Note 5 - Goodwill - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2023	Feb. 28, 2023	May 31, 2022
Goodwill	$ 2,005,701	$ 2,005,701	$ 2,641,305
Effect of foreign exchange		2,210	39,640
Impairments		(842,431)	(223,931)
Cannabis Segment [Member]
Goodwill	2,640,669	2,640,669	2,640,669
Impairments		(603,500)
Distribution Business [Member]
Goodwill	4,458	4,458	4,458
Beverage Alcohol Business [Member]
Goodwill	123,325	123,325	102,999
Wellness Business [Member]
Goodwill	77,470	$ 77,470	$ 77,470
Impairments	$ (15,000)

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Note 5 - Goodwill - Assets Acquired and Liabilities Assumed - Double Diamond Distillery (Details) - USD ($) $ in Thousands	Dec. 07, 2021	Feb. 28, 2023	May 31, 2022
Goodwill		$ 2,005,701	$ 2,641,305
Breckenridge [Member]
Shares	$ 114,068
Cash and cash equivalents	326
Accounts receivable	2,128
Prepaids and other current assets	367
Inventory	20,351
Capital assets	11,179
Goodwill	2,797
Total Assets	116,898
Accounts payable and accrued liabilities	2,228
Deferred tax liability	602
Total liabilities	2,830
Total net assets acquired	114,068
Breckenridge [Member] \| Customer Relationships [Member]
Definite-lived intangible assets	9,800
Breckenridge [Member] \| Intellectual Property, Trademarks and Brands [Member]
Definite-lived intangible assets	$ 69,950

Note 5 - Goodwill - Assets Acquired and Liabilities Assumed - Double Diamond Distillery (Details) (Parentheticals) - Breckenridge [Member]	Dec. 07, 2021
Customer Relationships [Member]
Estimated useful life (Year)	15 years
Intellectual Property, Trademarks and Brands [Member]
Estimated useful life (Year)	15 years

Note 5 - Goodwill - Assets Acquired and Liabilities Assumed - Montauk Brewing Company (Details) - USD ($) $ in Thousands	Nov. 07, 2022	Feb. 28, 2023	May 31, 2022
Goodwill		$ 2,005,701	$ 2,641,305
Acquisition of Montauk Brewing Company, Inc. [Member]
Cash	$ 28,688
Shares	6,422
Contingent consideration	10,245
Cash and cash equivalents	1,983
Accounts receivable	1,116
Prepaids and other current assets	467
Inventory	1,570
Capital assets	420
Goodwill	20,326
Total Assets	56,122
Accounts payable and accrued liabilities	1,580
Deferred tax liability	5,437
Other liabilities	3,750
Total liabilities	10,767
Total net assets acquired	45,355
Acquisition of Montauk Brewing Company, Inc. [Member] \| Customer Relationships [Member]
Definite-lived intangible assets	16,570
Acquisition of Montauk Brewing Company, Inc. [Member] \| Intellectual Property, Trademarks and Brands [Member]
Definite-lived intangible assets	12,430
Acquisition of Montauk Brewing Company, Inc. [Member] \| Noncompete Agreements [Member]
Definite-lived intangible assets	$ 1,240

Note 5 - Goodwill - Assets Acquired and Liabilities Assumed - Montauk Brewing Company (Details) (Parentheticals) - Acquisition of Montauk Brewing Company, Inc. [Member]	Nov. 07, 2022
Customer Relationships [Member]
Estimated useful life (Year)	15 years
Intellectual Property, Trademarks and Brands [Member]
Estimated useful life (Year)	15 years
Noncompete Agreements [Member]
Estimated useful life (Year)	5 years

Note 6 - Convertible Notes Receivable (Details Textual) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended
	Dec. 19, 2022 $ / shares	Jul. 12, 2022 USD ($) shares	Aug. 31, 2021 USD ($) shares	Feb. 28, 2023 USD ($) $ / shares	Feb. 28, 2022 USD ($)	Feb. 28, 2023 USD ($) $ / shares shares	Feb. 28, 2022 USD ($)	Feb. 21, 2023 $ / shares	Dec. 19, 2022 $ / shares	Jul. 12, 2022 $ / shares	May 31, 2022 $ / shares
Common Stock, Par or Stated Value Per Share (in CAD per share) \| $ / shares				$ 0.0001		$ 0.0001		$ 0.0001			$ 0.0001
Superhero Acquisition LP [Member]
Noncontrolling Interest, Ownership Percentage by Parent			68.00%	68.00%		68.00%
Reverse Stock Split [Member] \| HEXO [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	14
HEXO Convertible Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage		5.00%
Notes Receivable, Conversion Price (in CAD per share) \| (per share)	$ 42.00								$ 5.60	$ 0.40
Notes Receivable, Redemption Price, Percentage		115.00%
Interest Income, Purchased Receivables				$ 2,171		$ 5,549
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax				(63,597)		(63,597)
HEXO Convertible Notes Receivable [Member] \| Transaction (Income) Costs [Member]
Derivative, Gain (Loss) on Derivative, Net, Total						18,256
HEXO Convertible Notes Receivable [Member] \| Other Current Assets [Member]
Derivative Asset, Current				$ 0		$ 0
HEXO Convertible Notes Receivable [Member] \| Measurement Input, Forfeiture Rate [Member]
Notes Receivable, Measurement Input				0.30		0.30
HEXO Convertible Notes Receivable [Member] \| Measurement Input, Expected Term [Member]
Notes Receivable, Measurement Input				0.0350		0.0350
HEXO Convertible Notes Receivable [Member] \| Measurement Input, Price Volatility [Member]
Notes Receivable, Measurement Input				0.90		0.90
HEXO Convertible Notes Receivable [Member] \| Measurement Input, Expected Dividend Payment [Member]
Notes Receivable, Measurement Input				0		0
MM Notes [Member]
Financing Receivable, before Allowance for Credit Loss, Total			$ 165,799
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax				$ 82,100	$ (39,296)	$ 70,779	$ (56,250)
Notes Receivable, LIBOR Floor			2.50%
Notes Receivables, Other-than-temporary Impairment Expense				(117,778)		(117,778)
Interest Income, Purchased Convertible Notes Receivables				$ 3,474		$ 10,480
MM Notes [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Notes Receivable, Interest Rate, Basis Spread on Variable Rate			6.00%
MM Notes [Member] \| Measurement Input, Forfeiture Rate [Member]
Notes Receivable, Measurement Input			0	0.30		0.30
MM Notes [Member] \| Measurement Input, Price Volatility [Member]
Notes Receivable, Measurement Input			0.70
MM Notes [Member] \| Measurement Input, Expected Dividend Payment [Member]
Notes Receivable, Measurement Input			0
MM Notes [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Notes Receivable, Measurement Input			0.0350
MM Notes [Member] \| Measurement Input, Probability of Legalization [Member] \| Minimum [Member]
Notes Receivable, Measurement Input			0
MM Notes [Member] \| Measurement Input, Probability of Legalization [Member] \| Maximum [Member]
Notes Receivable, Measurement Input			0.60
Common Class 2 [Member]
Common Stock, Par or Stated Value Per Share (in CAD per share) \| $ / shares										$ 0.0001
Convertible Notes Receivable [Member]
Financing Receivable, before Allowance for Credit Loss, Total		$ 173,700
HEXO Convertible Notes Receivable [Member]
Notes Receivable, Redemption, Percentage of Principal Amount		110.00%
Asset Acquisition, Consideration Transferred, Total		$ 157,272
Asset Acquisition, Debt Issued		$ 50,000
Stock Issued During Period, Shares, Purchase of Assets (in shares) \| shares		33,314,412
HEXO Convertible Notes Receivable [Member] \| Common Class 2 [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares) \| shares						33,314,412
The MM Notes and MM Warrants [Member]
Stock Issued During Period, Shares, Acquisitions (in shares) \| shares			9,817,061
Stock Issued During Period, Value, Acquisitions			$ 117,804

Note 6 - Convertible Notes Receivable - Schedule of Convertible Notes Receivable (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
HEXO Convertible Note	$ 168,356	$ 111,200
Deduct - current portion	(0)	(0)
Total convertible notes receivable, non current portion	168,356	111,200
HEXO Convertible Notes Receivable [Member]
HEXO Convertible Note	93,675	0
MedMen Convertible Note [Member]
HEXO Convertible Note	$ 74,681	$ 111,200

Note 7 - Long Term Investments - Schedule of Long-term Investments (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Equity investments measured at fair value	$ 1,972	$ 4,347
Equity investments under measurement alternative	5,648	5,703
Total	$ 7,620	$ 10,050

Note 8 - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Trade payables	$ 67,065	$ 68,604
Accrued liabilities	68,316	57,497
Accrued payroll and employment related taxes	14,736	17,736
Income taxes payable	9,371	6,150
Accrued interest	3,796	6,772
Other accruals	138	672
Total	$ 163,422	$ 157,431

Note 9 - Bank Indebtedness (Details Textual) € in Thousands, $ in Thousands, $ in Millions	9 Months Ended
	Feb. 28, 2023 USD ($)	Feb. 28, 2023 CAD ($)	Feb. 28, 2023 EUR (€)
Four Twenty Corporation [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| $	$ 30,000
Long-Term Line of Credit, Total \| $	10,000
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| $		$ 1
Long-Term Line of Credit, Total \| $	0
Line of Credit [Member] \| CC Pharma GmbH [Member]
Long-Term Line of Credit, Total	$ 8,125		€ 7,663
Number of Debt Instruments	3	3	3
Line of Credit Facility, Remaining Borrowing Capacity \| €			€ 12,000
Line of Credit [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	75.00%
Line of Credit [Member] \| Euro Over Night Index Average [Member] \| CC Pharma GmbH [Member]
Debt Instrument, Basis Spread on Variable Rate	1.79%
Line of Credit [Member] \| Euro Interbank Offered Rate [Member] \| CC Pharma GmbH [Member]
Debt Instrument, Basis Spread on Variable Rate	3.682%
Operating Line of Credit One [Member] \| CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| €			8,000
Operating Line of Credit Two [Member] \| CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| €			3,500
Operating Line of Credit Three [Member] \| CC Pharma GmbH [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| €			€ 500

Note 10 - Long-term Debt (Details Textual) $ in Millions	Nov. 28, 2022 CAD ($)
Credit Facility Due in November 2022 [Member]
Debt Instrument, Face Amount	$ 66

Note 10 - Long-term Debt - Net Carrying Amount of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Credit Facility Due in November 2022 [Member]
Carrying amount of long-term debt	$ 47,630	$ 53,720
Term Loan Due in July 2023 [Member]
Carrying amount of long-term debt	11,322	12,750
Term Loan Due in April 2032 [Member]
Carrying amount of long-term debt	13,447	15,050
Term Loan Due in August 2026 [Member]
Carrying amount of long-term debt	371	462
Mortgage Payable Due in August 2026 [Member]
Carrying amount of long-term debt	2,140	2,327
Term Loan Due in December 2023, One [Member]
Carrying amount of long-term debt	1,060	1,878
Term Loan Due in December 2023, Two [Member]
Carrying amount of long-term debt	1,064	0
Term Loan Due in December 2023, Three [Member]
Carrying amount of long-term debt	1,060	1,878
Term Loan Due in April 2025 [Member]
Carrying amount of long-term debt	910	1,219
Term Loan Due in June 2025 [Member]
Carrying amount of long-term debt	994	1,307
Mortgage Payable Due in October 2030 [Member]
Carrying amount of long-term debt	21,041	21,561
Term Loan Due in March 2024 [Member]
Carrying amount of long-term debt	67,500	75,000
Long-term Debt, Excluding Convertible Debentures [Member]
Carrying amount of long-term debt	168,539	187,152
Unamortized financing fees	(1,228)	(1,450)
Net carrying amount	167,311	185,702
Less principal portion included in current liabilities	(77,892)	(67,823)
Total noncurrent portion of long-term debt	$ 89,419	$ 117,879

Note 10 - Long-term Debt - Net Carrying Amount of Long-term Debt Instruments (Details) (Parentheticals) € in Thousands, $ in Thousands, $ in Thousands	9 Months Ended			12 Months Ended
	Feb. 28, 2023 USD ($)	Feb. 28, 2023 CAD ($)	Feb. 28, 2023 EUR (€)	May 31, 2022 USD ($)	May 31, 2022 CAD ($)	May 31, 2022 EUR (€)	Feb. 28, 2023 CAD ($)	Feb. 28, 2023 EUR (€)	May 31, 2022 CAD ($)	May 31, 2022 EUR (€)
Credit Facility Due in November 2022 [Member]
Face amount							$ 66,000		$ 66,000
Term (Year)	3 years	3 years	3 years	3 years	3 years	3 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025	Nov. 30, 2025
Term Loan Due in July 2023 [Member]
Face amount							25,000		25,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	15 years	15 years	15 years	15 years	15 years	15 years
Maturity	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033	Jul. 31, 2033
Periodic payment		$ 194			$ 194
Term Loan Due in July 2023 [Member] \| Prime Rate [Member]
Variable rate	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%
Term Loan Due in April 2032 [Member]
Face amount							25,000		25,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	15 years	15 years	15 years	15 years	15 years	15 years
Maturity	Apr. 30, 2032	Apr. 30, 2032	Apr. 30, 2032	Apr. 30, 2032	Apr. 30, 2032	Apr. 30, 2032
Periodic payment		$ 190			$ 190
Term Loan Due in April 2032 [Member] \| Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in August 2026 [Member]
Face amount							1,250		1,250
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026
Periodic payment		$ 12			$ 12
Term Loan Due in August 2026 [Member] \| Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Mortgage Payable Due in August 2026 [Member]
Face amount							$ 3,750		$ 3,750
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Amortization period (Year)	20 years	20 years	20 years	20 years	20 years	20 years
Maturity	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026	Aug. 31, 2026
Periodic payment		$ 23			$ 23
Mortgage Payable Due in August 2026 [Member] \| Prime Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in December 2023, One [Member]
Face amount \| €								€ 5,000		€ 5,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment \| €			€ 250			€ 250
Term Loan Due in December 2023, One [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	1.79%	1.79%	1.79%	1.79%	1.79%	1.79%
Term Loan Due in December 2023, Two [Member]
Face amount \| €								1,500
Term (Year)	1 year	1 year	1 year
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment \| €			€ 100
Term Loan Due in December 2023, Two [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	1.79%	1.79%	1.79%
Term Loan Due in December 2023, Three [Member]
Face amount \| €								5,000		5,000
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment \| €			€ 250			€ 250
Term Loan Due in December 2023, Three [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	2.68%	2.68%	2.68%	2.68%	2.68%	2.68%
Term Loan Due in April 2025 [Member]
Face amount \| €								1,500		1,500
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025	Apr. 30, 2025
Periodic payment \| €			€ 98			€ 98
Term Loan Due in April 2025 [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%
Term Loan Due in June 2025 [Member]
Face amount \| €								€ 1,500		€ 1,500
Term (Year)	5 years	5 years	5 years	5 years	5 years	5 years
Maturity	Jun. 30, 2025	Jun. 30, 2025	Jun. 30, 2025	Jun. 30, 2025	Jun. 30, 2025	Jun. 30, 2025
Periodic payment \| €			€ 98			€ 98
Term Loan Due in June 2025 [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%
Mortgage Payable Due in October 2030 [Member]
Face amount	$ 22,635			$ 22,635
Term (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Amortization period (Year)	10 years	10 years	10 years	10 years	10 years	10 years
Maturity	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030	Oct. 31, 2030
Periodic payment	$ 57			$ 57
Mortgage Payable Due in October 2030 [Member] \| Euro Interbank Offered Rate [Member]
Variable rate	1.50%	1.50%	1.50%	1.50%	1.50%	1.50%
Term Loan Due in March 2024 [Member]
Face amount	$ 100,000			$ 100,000
Term (Year)	3 years	3 years	3 years	3 years	3 years	3 years
Maturity	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023
Periodic payment	$ 2,500			$ 2,500

Note 11 - Convertible Debentures Payable (Details Textual) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Jul. 12, 2022 USD ($) $ / shares	Feb. 28, 2023 USD ($) $ / shares	Feb. 28, 2023 USD ($) $ / shares	Aug. 31, 2022 USD ($)	May 31, 2022
HT Investments MA LLC Note [Member]
Debt Instrument, Face Amount	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	4.00%	4.00%	4.00%		4.00%
Debt Instrument, Maturity Date	Sep. 01, 2023
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 9,055
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares	$ 4.03
APHA 24 [Member]
Debt Instrument, Face Amount		$ 259,240	$ 259,240
Debt Instrument, Interest Rate, Stated Percentage		5.25%	5.25%		5.25%
Debt Instrument, Maturity Date			Jun. 01, 2024
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 11.20	$ 11.20
Debt Instrument, Convertible, Multiples of Principal Amount		$ 1	$ 1
Debt Instrument, Convertible, Earliest Date			Dec. 01, 2023
Debt Instrument, Convertible, Latest Date			Jun. 01, 2024
Debt Instrument, Convertible, Threshold Trading Days			20
Debt Instrument, Convertible, Threshold Consecutive Trading Days			30
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			130.00%
Debt Instrument, Convertible, Threshold Trading Days, Measurement Period (Year)			5 years
Debt Instrument, Convertible, Threshold Consecutive Trading Days, Measurement Period (Year)			5 years
Debt Instrument, Convertible, Minimum Threshold Percentage During Measurement Period			98.00%
Debt Instrument, Redemption Price, Including Interest, Percentage			100.00%
TLRY 23 [Member]
Debt Instrument, Interest Rate, Stated Percentage		5.00%	5.00%		5.00%
Debt Instrument, Maturity Date			Sep. 30, 2023
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 167.41	$ 167.41
Debt Instrument, Convertible, Multiples of Principal Amount				$ 1
Debt Instrument, Convertible, Earliest Date			Apr. 01, 2023
Debt Instrument, Convertible, Latest Date			Sep. 30, 2023
Debt Instrument, Repurchased Face Amount		$ 50,000	$ 50,000
Debt Instrument, Repurchase Amount		$ 48,975	48,975
Debt Instrument, Unamortized Discount, Increase (Decrease)			$ (918)
Long-Term Debt, Term (Year)		5 years	5 years
Debt Instrument, Convertible, Conversion Ratio			5.9735
Debt Instrument, Convertible, Number of Equity Instruments			835,275
Debt Instrument, Outstanding Principal Amount		$ 139,830	$ 139,830
Debt Instrument, Interest Rate, Effective Percentage				6.90%
Interest Expense, Debt, Total		1,748	6,077
Amortization of Debt Discount (Premium)		$ 630	2,169
TLRY 23 [Member] \| Nonoperating Income (Expense) [Member]
Gain (Loss) on Repurchase of Debt Instrument			$ 191

Note 11 - Convertible Debentures Payable - Net Carrying Amount of Convertible Debentures (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Feb. 28, 2023	May 31, 2022
Convertible debentures	$ 407,169	$ 401,949
Convertible debentures	407,169	401,949
Deduct - current portion	184,082	0
Total convertible debentures payable, non current portion	223,087	401,949
HT Investments MA LLC Note [Member]
Convertible debentures	45,762	0
Convertible debentures	45,762	0
Carrying amount of long-term debt	50,000	0
Unamortized discount	(4,238)	0
APHA 24 [Member]
Convertible debentures	223,087	216,753
Convertible debentures	223,087	216,753
Carrying amount of long-term debt	350,000	350,000
Debt settlement	(90,760)	(90,760)
Fair value adjustment	(36,153)	(42,487)
TLRY 23 [Member]
Convertible debentures	138,320	185,196
Convertible debentures	138,320	185,196
Carrying amount of long-term debt	277,856	277,856
Unamortized discount	(1,510)	(4,634)
Debt settlement	$ (138,026)	$ (88,026)

Note 11 - Convertible Debentures Payable - Net Carrying Amount of Convertible Debentures (Details) (Parentheticals)	Feb. 28, 2023	Jul. 12, 2022	May 31, 2022
HT Investments MA LLC Note [Member]
Interest rate	4.00%	4.00%	4.00%
APHA 24 [Member]
Interest rate	5.25%		5.25%
TLRY 23 [Member]
Interest rate	5.00%		5.00%

Note 12 - Warrant Liability (Details Textual) - $ / shares	Feb. 28, 2023	May 31, 2022
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,209,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.15	$ 5.95
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Percentage of Daily Cash Penalty	1.00%
Fair Value, Inputs, Level 3 [Member]
Estimated Fair Value of Warrant Liability Per Warrant (in dollars per share)	$ 1.19
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0394
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.70
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	2.55
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Conversion Price [Member]
Warrants and Rights Outstanding, Measurement Input	3.15
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	2.83

Note 13 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands		3 Months Ended					9 Months Ended
	Jul. 12, 2022 $ / shares shares	Feb. 28, 2023 USD ($) $ / shares shares	Nov. 30, 2022 USD ($)	Aug. 31, 2022 USD ($)	Feb. 28, 2022 USD ($) shares	Nov. 30, 2021 USD ($)	Feb. 28, 2023 USD ($) $ / shares shares	Feb. 28, 2022 USD ($) shares	Feb. 21, 2023 $ / shares	May 31, 2022 $ / shares shares
Preferred Stock, Votes									1,000
Common Stock, Par or Stated Value Per Share (in CAD per share) \| $ / shares		$ 0.0001					$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock and Common Stock, Shares Authorized (in shares)		990,000,000					990,000,000
Common Stock, Shares Authorized (in shares)		980,000,000					980,000,000			980,000,000
Common Stock, Shares, Issued (in shares)		617,857,031					617,857,031			532,674,887
Common Stock, Shares, Outstanding, Ending Balance (in shares)		617,857,031					617,857,031			532,674,887
Preferred Stock, Shares Authorized (in shares)		10,000,000					10,000,000			10,000,000
Preferred Stock, Shares Issued (in shares)		120,000					120,000			0
Stock Issued During Period, Value, Equity Financing \| $				$ 129,593
Stock Issued During Period, Value, Settlement of Financing Liability \| $		$ 7,678	$ 6,474	$ 5,064		$ 0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)		120,000					120,000			0
Share-Based Payment Arrangement, Expense \| $		$ 9,630			$ 9,355		$ 29,766	$ 27,025
Time-based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0			0		6,004,995	69,508
Performance-based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0			0		2,634,744	1,414,666
HEXO Convertible Notes Receivable [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	33,314,412
Common Class 1 [Member]
Common Stock, Par or Stated Value Per Share (in CAD per share) \| $ / shares									$ 0.0001
Common Stock, Shares Authorized (in shares)		243,333,333					243,333,333
Common Stock, Shares, Issued (in shares)		0					0
Common Stock, Shares, Outstanding, Ending Balance (in shares)		0					0
Common Class 2 [Member]
Common Stock, Par or Stated Value Per Share (in CAD per share) \| $ / shares	$ 0.0001
Common Stock, Shares Authorized (in shares)		736,666,667					736,666,667
Common Stock, Shares, Issued (in shares)		613,181,559					613,181,559
Common Stock, Shares, Outstanding, Ending Balance (in shares)		613,181,559					613,181,559
Stock Issued During Period, Shares, Settlement of Financing Liability (in shares)							15,994,406
Stock Issued During Period, Value, Settlement of Financing Liability \| $							$ 59,731
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total (in shares)							1,683,656
Common Class 2 [Member] \| Acquisition of Montauk Brewing Company, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions (in shares)							1,708,521
Common Class 2 [Member] \| HEXO Convertible Notes Receivable [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)							33,314,412
Common Class 2 [Member] \| At-the-Market Program [Member]
Stock Issued During Period, Shares, Equity Financing (in shares)							32,481,149
Stock Issued During Period, Value, Equity Financing \| $							$ 132,238
Payments of Stock Issuance Costs \| $							2,645
Net Proceeds from Issuance of Common Stock \| $							$ 129,593
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)		10,000,000					10,000,000
Preferred Stock, Shares Issued (in shares)		120,000					120,000
Stock Issued During Period, Shares, Settlement of Financing Liability (in shares)							120,000
Stock Issued During Period, Value, Settlement of Financing Liability \| $							$ 334

Note 13 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Stock-based compensation expense	$ 9,630	$ 9,355	$ 29,766	$ 27,025
Share-Based Payment Arrangement, Option [Member]
Stock-based compensation expense	20	273	644	4,968
Restricted Stock Units (RSUs) [Member]
Stock-based compensation expense	$ 9,610	$ 9,082	$ 29,122	$ 22,057

Note 14 - Accumulated Other Comprehensive Income (Loss) - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Balance	$ 4,483,146	$ 4,563,182	$ 4,441,366	$ 4,472,989	$ 4,441,366	$ 4,465,313
Other comprehensive loss	101,735			(20,798)	(3,322)	(170,891)
Balance	3,406,771	4,483,146	4,563,182	$ 4,661,013	3,406,771	$ 4,661,013
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(26,110)	(2,030)	54,413		54,413
Other comprehensive loss	(16,838)	(24,080)	(56,443)
Balance	(42,948)	(26,110)	(2,030)		(42,948)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Balance	(95,345)	(77,702)	(75,177)		(75,177)
Other comprehensive loss	95,345	(17,643)	(2,525)
Balance	0	(95,345)	(77,702)		0
Unrealized Loss on Available for Sale Debt Securities [Member]
Balance	(121,455)	(79,732)	(20,764)		(20,764)
Other comprehensive loss	78,507	(41,723)	(58,968)
Balance	$ (42,948)	$ (121,455)	$ (79,732)		$ (42,948)

Amount after tax and reclassification adjustments of other comprehensive income (loss).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Note 15 - Non-controlling Interests (Details Textual)	Feb. 28, 2023	Aug. 31, 2021
Superhero Acquisition LP [Member]
Noncontrolling Interest, Ownership Percentage by Parent	68.00%	68.00%
CC Pharma Nordic ApS [Member]
Noncontrolling Interest, Ownership Percentage by Parent	75.00%
Aphria Diamond [Member]
Noncontrolling Interest, Ownership Percentage by Parent	51.00%
ColCanna S.A.S. [Member]
Noncontrolling Interest, Ownership Percentage by Parent	90.00%

Note 15 -Non-controlling Interests - Summary of Balance Sheet Information (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Current assets	$ 758,512	$ 803,503
Current liabilities	(469,682)	(280,342)
Superhero Acquisition LP [Member]
Current assets	0	0
Non-current assets	74,681	111,200
Current liabilities	0	0
Non-current liabilities	0	0
Net assets	74,681	111,200
CC Pharma Nordic ApS [Member]
Current assets	163	485
Non-current assets	0	158
Current liabilities	(713)	(642)
Non-current liabilities	(405)	(410)
Net assets	(955)	(409)
Aphria Diamond [Member]
Current assets	94,103	20,546
Non-current assets	139,749	152,786
Current liabilities	(13,468)	(63,196)
Non-current liabilities	(176,071)	(29,653)
Net assets	44,313	80,483
ColCanna S.A.S. [Member]
Current assets	157	193
Non-current assets	3,025	93,738
Current liabilities	(39)	(53)
Non-current liabilities	(6,455)	(6,537)
Net assets	(3,312)	87,341
Subsidiaries [Member]
Current assets	94,423	21,224
Non-current assets	217,455	357,882
Current liabilities	(14,220)	(63,891)
Non-current liabilities	(182,931)	(36,600)
Net assets	$ 114,727	$ 278,615

Note 15 - Non-controlling Interests - Summary of Income Statement Information (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 28, 2023	Nov. 30, 2022	Aug. 31, 2022	Feb. 28, 2022	Nov. 30, 2021	Aug. 31, 2021	Feb. 28, 2023	Feb. 28, 2022
Net (loss) income	$ (1,195,752)			$ 52,475			$ (1,323,181)	$ 23,668
Other comprehensive (loss) income	101,735			(20,798)			(3,322)	(170,891)
Net comprehensive (loss) income	(1,094,017)	$ (103,875)	$ (128,611)	31,677	$ (42,875)	$ (136,025)	(1,326,503)	(147,223)
Comprehensive (loss) income attributable to NCI	$ (1,526)			$ (2,928)			9,624	3,095
Subsidiaries [Member]
Revenue							99,086	88,824
Total expenses							253,267	40,512
Net (loss) income							(154,181)	48,312
Other comprehensive (loss) income							70,431	(60,283)
Net comprehensive (loss) income							(83,750)	(11,971)
Comprehensive (loss) income attributable to NCI							656	3,095
Additional income attributable to NCI							8,968
Net comprehensive (loss) income attributable to NCI							9,624
Superhero Acquisition LP [Member]
Revenue							0	0
Total expenses							107,297	(7,568)
Net (loss) income							(107,297)	7,568
Other comprehensive (loss) income							70,778	(55,601)
Net comprehensive (loss) income							$ (36,519)	$ (48,033)
Non-controlling interest %	32.00%			32.00%			32.00%	32.00%
Comprehensive (loss) income attributable to NCI							$ (11,686)	$ (15,371)
Additional income attributable to NCI							0
Net comprehensive (loss) income attributable to NCI							(11,686)
CC Pharma Nordic ApS [Member]
Revenue							126	354
Total expenses							659	431
Net (loss) income							(533)	(77)
Other comprehensive (loss) income							(13)	30
Net comprehensive (loss) income							$ (546)	$ (47)
Non-controlling interest %	25.00%			25.00%			25.00%	25.00%
Comprehensive (loss) income attributable to NCI							$ (137)	$ (12)
Additional income attributable to NCI							0
Net comprehensive (loss) income attributable to NCI							(137)
Aphria Diamond [Member]
Revenue							98,960	88,470
Total expenses							54,285	47,841
Net (loss) income							44,675	40,629
Other comprehensive (loss) income							(707)	(2,509)
Net comprehensive (loss) income							$ 43,968	$ 38,120
Non-controlling interest %	49.00%			49.00%			49.00%	49.00%
Comprehensive (loss) income attributable to NCI							$ 21,544	$ 18,679
Additional income attributable to NCI							8,968
Net comprehensive (loss) income attributable to NCI							30,512
ColCanna S.A.S. [Member]
Revenue							0	0
Total expenses							91,026	(192)
Net (loss) income							(91,026)	192
Other comprehensive (loss) income							373	(2,203)
Net comprehensive (loss) income							$ (90,653)	$ (2,011)
Non-controlling interest %	10.00%			10.00%			10.00%	10.00%
Comprehensive (loss) income attributable to NCI							$ (9,065)	$ (201)
Additional income attributable to NCI							0
Net comprehensive (loss) income attributable to NCI							$ (9,065)

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Income Tax Expense (Benefit), Total	$ (10,811)	$ (1,830)	$ (15,313)	$ (2,739)

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Note 17 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions			3 Months Ended	9 Months Ended
	Feb. 27, 2023	Jul. 15, 2022	Feb. 28, 2023	Feb. 28, 2023
Loss Contingency Accrual, Ending Balance			$ 25.0	$ 25.0
Tilray Brands, Inc. Reorganization Litigation (Delaware, New York) Special Litigation Committee [Member]
Litigation Settlement, Amount Awarded from Other Party	$ 39.9	$ 26.9	$ 33.0	$ 33.0

Note 17 - Commitments and Contingencies - Schedule of Commitments (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Total	$ 649,920
Total, 2024	293,101
Total, 2025	275,912
Total, 2026	41,275
Total, 2027	4,982
Total, thereafter	34,650
Material Purchase Obligations [Member]
Purchase obligations, total	26,878
Purchase obligations, 2024	19,946
Purchase obligations, 2025	5,515
Purchase obligations, 2026	840
Purchase obligations, 2027	239
Purchase obligations, thereafter	338
Capital Addition Purchase Commitments [Member]
Purchase obligations, total	5,433
Purchase obligations, 2024	5,433
Purchase obligations, 2025	0
Purchase obligations, 2026	0
Purchase obligations, 2027	0
Purchase obligations, thereafter	0
Long-term Debt, Excluding Convertible Debentures [Member]
Long-term debt repayment	168,539	$ 187,152
Long-term debt repayment, 2024	77,892
Long-term debt repayment, 2025	11,157
Long-term debt repayment, 2026	40,435
Long-term debt repayment, 2027	4,743
Long-term debt repayment, thereafter	34,312
Convertible Debt [Member]
Long-term debt repayment	449,070
Long-term debt repayment, 2024	189,830
Long-term debt repayment, 2025	259,240
Long-term debt repayment, 2026	0
Long-term debt repayment, 2027	0
Long-term debt repayment, thereafter	$ 0

Note 17 - Commitments and Contingencies - Future Undiscounted Payment Associated with Lease Liabilities (Details) $ in Thousands	Feb. 28, 2023 USD ($)
2023	$ 3,979
2024	3,337
2025	3,521
2026	3,417
Thereafter	4,928
Total minimum lease payments	19,182
Imputed interest	(8,056)
Obligations recognized	$ 11,126

Note 18 - Net Revenue (Details Textual)	9 Months Ended
Note 18 - Net Revenue (Details Textual)	Feb. 28, 2023
Number of Operating Segments	4

Note 18 - Net Revenue - Components of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Net revenue	$ 145,589	$ 151,871	$ 442,936	$ 475,047
Cannabis Segment [Member]
Excise taxes	(13,569)	(14,133)	(47,486)	(48,271)
Net revenue	47,549	55,045	156,017	184,269
Beverage Alcohol Business [Member]
Excise taxes	(1,301)	(876)	(4,520)	(2,735)
Net revenue	20,640	19,597	62,689	48,765
Revenue	21,941	20,473	67,209	51,500
Distribution Business [Member]
Net revenue	65,385	62,532	186,158	198,587
Wellness Business [Member]
Net revenue	$ 12,015	$ 14,697	$ 38,072	$ 43,426

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Note 19 - Cost of Goods Sold - Components of Cost of Goods Sold (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Cost of goods sold	$ 157,288	$ 112,042	$ 363,139	$ 351,497
Cannabis Segment [Member]
Cost of goods sold	80,362	37,042	137,800	122,492
Beverage Alcohol Business [Member]
Cost of goods sold	10,663	8,091	32,932	20,674
Distribution Business [Member]
Cost of goods sold	57,964	57,566	165,443	178,093
Wellness Business [Member]
Cost of goods sold	$ 8,299	$ 9,343	$ 26,964	$ 30,238

Note 20 - General and Administrative Expenses - Components of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Executive compensation	$ 2,754	$ 4,238	$ 9,359	$ 9,565
Office and general	6,799	4,012	20,011	21,755
Salaries and wages	13,621	14,076	38,407	37,536
Share-Based Payment Arrangement, Expense	9,630	9,355	29,766	27,025
Insurance	3,159	4,835	8,588	14,461
Professional fees	1,165	3,601	5,385	9,669
Loss (gain) on sale of capital assets	(15)	(861)	(2)	(631)
Insurance proceeds	0	(4,032)	0	(4,032)
Travel and accommodation	1,104	1,102	3,484	2,876
Rent	782	2,119	2,387	3,177
Total	$ 38,999	$ 38,445	$ 117,385	$ 121,401

Note 21 - Non-operating Income (Expense) - Components of Non-operating Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Change in fair value of convertible debenture payable	$ 207	$ 56,128	$ (20,375)	$ 151,851
Change in fair value of warrant liability	5,256	21,089	6,841	58,802
Foreign exchange loss	(1,955)	(2,548)	(26,621)	(18,452)
Loss on long-term investments	(925)	(3,326)	(2,529)	(6,834)
Other non-operating (losses) gains, net	(1,370)	(306)	(7,545)	962
Total	$ 1,213	$ 71,037	$ (50,229)	$ 186,329

Note 22 - Fair Value Measurements (Details Textual) $ in Thousands	Feb. 28, 2023 USD ($)	May 31, 2022 USD ($)
Long-Term Debt, Percentage Bearing Fixed Interest, Amount	$ 0	$ 20,358
SweetWater [Member] \| Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.05
SweetWater [Member] \| Measurement Input, Probability of Achievement [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.25
Acquisition of Montauk Brewing Company, Inc. [Member] \| Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.114
Acquisition of Montauk Brewing Company, Inc. [Member] \| Measurement Input, Probability of Achievement [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.80

Note 22 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Feb. 28, 2023	May 31, 2022
Equity investments measured at fair value	$ 1,972	$ 4,347
Contingent consideration	16,219	16,007
Fair Value, Recurring [Member]
Cash and cash equivalents	164,997	415,909
Marketable Securities	243,286
Convertible notes receivable	168,356	111,200
Equity investments measured at fair value	7,620	10,050
Warrant liability	7,414	14,255
Contingent consideration	26,815	16,007
Total recurring fair value measurements	326,943	290,144
Fair Value, Recurring [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	223,087	216,753
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	164,997	415,909
Marketable Securities	243,286
Convertible notes receivable	0	0
Equity investments measured at fair value	376	1,878
Warrant liability	(0)	(0)
Contingent consideration	(0)	(0)
Total recurring fair value measurements	408,659	417,787
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	(0)	(0)
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	0	0
Marketable Securities	0
Convertible notes receivable	0	0
Equity investments measured at fair value	1,596	2,469
Warrant liability	(0)	(0)
Contingent consideration	(0)	(0)
Total recurring fair value measurements	1,596	2,469
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	(0)	(0)
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	0	0
Marketable Securities	0
Convertible notes receivable	168,356	111,200
Equity investments measured at fair value	5,648	5,703
Warrant liability	7,414	14,255
Contingent consideration	26,815	16,007
Total recurring fair value measurements	(83,312)	(130,112)
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| APHA 24 [Member]
APHA 24 Convertible debenture	$ 223,087	$ 216,753

Note 22 - Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Feb. 28, 2023 USD ($)
Balance	$ (135,815)
Additions	157,507
Unrealized gain (loss) on fair value	70,723
Impairments	(181,375)
Balance	(88,960)
Debt Securities [Member]
Balance	(216,753)
Additions	0
Unrealized gain (loss) on fair value	(6,334)
Impairments	0
Balance	(223,087)
Long-Term Debt [Member] \| APHA 24 [Member]
Balance	111,200
Additions	167,752
Unrealized gain (loss) on fair value	70,779
Impairments	(181,375)
Balance	168,356
Warrant Liability [Member]
Balance	(14,255)
Additions	0
Unrealized gain (loss) on fair value	6,841
Impairments	0
Balance	(7,414)
Contingent Consideration [Member]
Balance	(16,007)
Additions	(10,245)
Unrealized gain (loss) on fair value	(563)
Impairments	0
Balance	$ (26,815)

Note 22 - Fair Value Measurements - Inputs Used to Recognize Unrealized Gain (Loss) on Fair Value (Details)	Feb. 28, 2023
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Price Volatility [Member]
APHA Convertible debentures	0.70
Warrant liability	0.70
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Forfeiture Rate [Member]
APHA Convertible debentures	0.30
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Expected Term [Member]
Warrant liability	2.0
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Discount Rate [Member] \| Minimum [Member]
Convertible notes receivable	0.17
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Discount Rate [Member] \| Maximum [Member]
Convertible notes receivable	0.22
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Conversion Rate [Member] \| Minimum [Member]
Convertible notes receivable	0
Valuation Technique, Option Pricing Model [Member] \| Measurement Input, Conversion Rate [Member] \| Maximum [Member]
Convertible notes receivable	0.60
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Expected Term [Member]
APHA Convertible debentures	1.3
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Discount Rate [Member] \| Minimum [Member]
Contingent consideration	0.05
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Discount Rate [Member] \| Maximum [Member]
Contingent consideration	0.11
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Probability of Achievement [Member] \| Minimum [Member]
Contingent consideration	0.25
Valuation Technique, Discounted Cash Flow [Member] \| Measurement Input, Probability of Achievement [Member] \| Maximum [Member]
Contingent consideration	0.80

Note 23 - Segment Reporting (Details Textual) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 28, 2023 USD ($)	Feb. 28, 2023 USD ($)	Jul. 12, 2022 USD ($)
Number of Reportable Segments		4
Advisory Services Agreement With HEXO [Member]
Advisory Services Agreement, Contract Amount			$ 18,000
Advisory Services Agreement With HEXO [Member] \| Advisory Services Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 8,667	$ 24,302

Note 23 - Segment Reporting - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Net revenue	$ 145,589	$ 151,871	$ 442,936	$ 475,047
Cost of goods sold	157,288	112,042	363,139	351,497
Gross profit (loss)	(11,699)	39,829	79,797	123,550
Cannabis Segment [Member]
Net revenue	47,549	55,045	156,017	184,269
Cost of goods sold	80,362	37,042	137,800	122,492
Gross profit (loss)	(32,813)	18,003	18,217	61,777
Excise taxes	(13,569)	(14,133)	(47,486)	(48,271)
Cannabis Segment [Member] \| Medical Cannabis Products [Member]
Revenue	6,035	7,050	18,920	23,353
Cannabis Segment [Member] \| Adult-use Cannabis Products [Member]
Revenue	45,318	43,504	156,063	162,632
Cannabis Segment [Member] \| Wholesale Cannabis Products [Member]
Revenue	58	2,804	686	6,763
Cannabis Segment [Member] \| International Cannabis Products [Member]
Revenue	9,707	15,820	27,834	39,792
Distribution Business [Member]
Net revenue	65,385	62,532	186,158	198,587
Cost of goods sold	57,964	57,566	165,443	178,093
Gross profit (loss)	7,421	4,966	20,715	20,494
Beverage Alcohol Business [Member]
Net revenue	20,640	19,597	62,689	48,765
Cost of goods sold	10,663	8,091	32,932	20,674
Gross profit (loss)	9,977	11,506	29,757	28,091
Revenue	21,941	20,473	67,209	51,500
Excise taxes	(1,301)	(876)	(4,520)	(2,735)
Wellness Business [Member]
Net revenue	12,015	14,697	38,072	43,426
Cost of goods sold	8,299	9,343	26,964	30,238
Gross profit (loss)	$ 3,716	$ 5,354	$ 11,108	$ 13,188

Note 23 - Segment Reporting - Geographic Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Net revenue	$ 145,589	$ 151,871	$ 442,936	$ 475,047
North America [Member]
Net revenue	70,463	73,234	228,866	236,220
EMEA [Member]
Net revenue	71,111	74,671	199,867	225,596
Rest of World [Member]
Net revenue	$ 4,015	$ 3,966	$ 14,203	$ 13,231